Skip to content
Prostate Cancer Research Center

Faculty of Medicine and Health Technology

arkistossa

Auvinen Group: Epidemiology
Bova Group: PELICAN-Personalized Cancer Medicine
Emmert-Streib Group: Group Predictive Society and Data Analytics Lab
Granberg Group: Cancer Regulation and Immunology
Murtola Group: Pharmacoepidemiology and Chemoprevention
Nykter Group: Computational Biology
Ruusuvuori Group: Bioimage Informatics
Schleutker Group: Genetic Predisposition to Prostate Cancer
Tammela Group: Molecular Biology
Tolonen Group: Histopathology

Auvinen Group

Epidemiology

 

2020
  1. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Seasonal changes in occurrence and severity of lower urinary tract symptoms-Tampere Aging Male Urologic Study (TAMUS). Low Urin Tract Symptoms. 2020; :. doi: 10.1111/luts.12353. PubMed PMID:33034153 .
  2. Niskanen, L, Partonen, T, Auvinen, A, Haukka, J. Trends and predictors in all-cause and cause-specific mortality in diabetic and reference populations during 21 years of follow-up. J Epidemiol Community Health. 2020;74 (11):950-956. doi: 10.1136/jech-2019-213602. PubMed PMID:32620580 .
  3. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
  4. Omar, MI, Roobol, MJ, Ribal, MJ, Abbott, T, Agapow, PM, Araujo, S et al.. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research. 2020;17 (8):482. doi: 10.1038/s41585-020-0355-3. PubMed PMID:32587405 .
  5. Talala, K, Heinävaara, S, Taari, K, Tammela, TLJ, Kujala, P, Stenman, UH et al.. Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. 2020;9 (15):5643-5654. doi: 10.1002/cam4.3181. PubMed PMID:32500650 PubMed Central PMC7402814.
  6. Omar, MI, Roobol, MJ, Ribal, MJ, Abbott, T, Agapow, PM, Araujo, S et al.. Introducing PIONEER: a project to harness big data in prostate cancer research. 2020;17 (6):351-362. doi: 10.1038/s41585-020-0324-x. PubMed PMID:32461687 .
  7. Tettamanti, G, Auvinen, A, Åkerstedt, T, Kojo, K, Ahlbom, A, Heinävaara, S et al.. Long-term effect of mobile phone use on sleep quality: Results from the cohort study of mobile phone use and health (COSMOS). 2020;140 :105687. doi: 10.1016/j.envint.2020.105687. PubMed PMID:32276731 PubMed Central PMC7272128.
  8. Kilpeläinen, TP, Talala, K, Taari, K, Raitanen, J, Kujala, P, Pylväläinen, J et al.. Patients’ education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer. Eur J Cancer. 2020;130 :204-210. doi: 10.1016/j.ejca.2020.02.045. PubMed PMID:32229417 .
  9. Karalexi, MA, Dessypris, N, Ma, X, Spector, LG, Marcotte, E, Clavel, J et al.. Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. Eur J Cancer. 2020;130 :1-11. doi: 10.1016/j.ejca.2020.01.018. PubMed PMID:32163883 .
  10. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). 2020;105 (3):849-850. doi: 10.3324/haematol.2019.245704. PubMed PMID:32115415 PubMed Central PMC7049358.
  11. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
  12. Mazzei-Abba, A, Folly, CL, Coste, A, Wakeford, R, Little, MP, Raaschou-Nielsen, O et al.. Epidemiological studies of natural sources of radiation and childhood cancer: current challenges and future perspectives. 2020;40 (1):R1-R23. doi: 10.1088/1361-6498/ab5a38. PubMed PMID:31751953 .
  13. Kalapara, AA, Verbeek, JFM, Nieboer, D, Fahey, M, Gnanapragasam, V, Van Hemelrijck, M et al.. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative. 2020;3 (1):80-91. doi: 10.1016/j.euo.2019.08.014. PubMed PMID:31564531 .
  14. Seibold, P, Auvinen, A, Averbeck, D, Bourguignon, M, Hartikainen, JM, Hoeschen, C et al.. Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. 2020;96 (3):324-339. doi: 10.1080/09553002.2019.1665209. PubMed PMID:31539290 .
  15. Pesonen, JS, Cartwright, R, Vernooij, RWM, Aoki, Y, Agarwal, A, Mangera, A et al.. The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. J Urol. 2020;203 (3):486-495. doi: 10.1097/JU.0000000000000463. PubMed PMID:31364920 .

Search PubMed

2019
  1. Nikkilä, A, Arvela, H, Mehtonen, J, Raitanen, J, Heinäniemi, M, Lohi, O et al.. Predicting residential radon concentrations in Finland: Model development, validation, and application to childhood leukemia. 2020;46 (3):278-292. doi: 10.5271/sjweh.3867. PubMed PMID:31763683 .
  2. Mazzei-Abba, A, Folly, CL, Coste, A, Wakeford, R, Little, MP, Raaschou-Nielsen, O et al.. Epidemiological studies of natural sources of radiation and childhood cancer: current challenges and future perspectives. 2020;40 (1):R1-R23. doi: 10.1088/1361-6498/ab5a38. PubMed PMID:31751953 .
  3. Pylväläinen, J, Talala, K, Murtola, T, Taari, K, Raitanen, J, Tammela, TL et al.. Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time. 2019;11 :923-932. doi: 10.2147/CLEP.S218697. PubMed PMID:31695505 PubMed Central PMC6805117.
  4. Booth, N, Rissanen, P, Tammela, TLJ, Kujala, P, Stenman, UH, Taari, K et al.. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. 2019;14 (11):e0224479. doi: 10.1371/journal.pone.0224479. PubMed PMID:31689326 PubMed Central PMC6830755.
  5. Kalapara, AA, Verbeek, JFM, Nieboer, D, Fahey, M, Gnanapragasam, V, Van Hemelrijck, M et al.. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative. 2020;3 (1):80-91. doi: 10.1016/j.euo.2019.08.014. PubMed PMID:31564531 .
  6. Seibold, P, Auvinen, A, Averbeck, D, Bourguignon, M, Hartikainen, JM, Hoeschen, C et al.. Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. 2020;96 (3):324-339. doi: 10.1080/09553002.2019.1665209. PubMed PMID:31539290 .
  7. Drost, FH, Nieboer, D, Morgan, TM, Carroll, PR, Roobol, MJ, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium et al.. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. 2019;76 (5):693-702. doi: 10.1016/j.eururo.2019.07.041. PubMed PMID:31451332 .
  8. Pesonen, JS, Cartwright, R, Vernooij, RWM, Aoki, Y, Agarwal, A, Mangera, A et al.. The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis. J Urol. 2020;203 (3):486-495. doi: 10.1097/JU.0000000000000463. PubMed PMID:31364920 .
  9. Talibov, M, Olsson, A, Bailey, H, Erdmann, F, Metayer, C, Magnani, C et al.. Parental occupational exposure to low-frequency magnetic fields and risk of leukaemia in the offspring: findings from the Childhood Leukaemia International Consortium (CLIC). 2019;76 (10):746-753. doi: 10.1136/oemed-2019-105706. PubMed PMID:31358566 PubMed Central PMC6817988.
  10. Barchuk, A, Bespalov, A, Huhtala, H, Chimed, T, Belyaev, A, Moore, M et al.. Productivity losses associated with premature mortality due to cancer in Russia: A population-wide study covering 2001-2030. 2019;47 (5):482-491. doi: 10.1177/1403494819845565. PubMed PMID:31313982 PubMed Central PMC6651608.
  11. Auvinen, A, Feychting, M, Ahlbom, A, Hillert, L, Elliott, P, Schüz, J et al.. Headache, tinnitus and hearing loss in the international Cohort Study of Mobile Phone Use and Health (COSMOS) in Sweden and Finland. 2019;48 (5):1567-1579. doi: 10.1093/ije/dyz127. PubMed PMID:31302690 PubMed Central PMC6857740.
  12. van der Kwast, TH, Helleman, J, Nieboer, D, Bruinsma, SM, Roobol, MJ, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium et al.. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. 2019;2 (3):333-336. doi: 10.1016/j.euo.2018.08.017. PubMed PMID:31200849 .
  13. Starck, C, Nevalainen, O, Auvinen, A, Eriksson, K. Fertility and marital status in adults with childhood onset epilepsy: A population-based cohort study. 2019;60 (7):1438-1444. doi: 10.1111/epi.16018. PubMed PMID:31121078 .
  14. Heijnsdijk, EAM, Adolfsson, J, Auvinen, A, Roobol, MJ, Hugosson, J, de Koning, HJ et al.. The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers. 2019;76 (3):276-279. doi: 10.1016/j.eururo.2019.04.007. PubMed PMID:31031050 PubMed Central PMC6800079.
  15. Natukka, T, Raitanen, J, Haapasalo, H, Auvinen, A. Incidence trends of adult malignant brain tumors in Finland, 1990-2016. 2019;58 (7):990-996. doi: 10.1080/0284186X.2019.1603396. PubMed PMID:30985227 .
  16. Carlsson, SV, Månsson, M, Moss, S, Kwiatkowski, M, Recker, F, Tammela, TLJ et al.. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. Eur Urol. 2019;75 (6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. PubMed PMID:30928162 PubMed Central PMC7526685.
  17. Hugosson, J, Roobol, MJ, Månsson, M, Tammela, TLJ, Zappa, M, Nelen, V et al.. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76 (1):43-51. doi: 10.1016/j.eururo.2019.02.009. PubMed PMID:30824296 PubMed Central PMC7513694.
  18. Panagopoulou, P, Skalkidou, A, Marcotte, E, Erdmann, F, Ma, X, Heck, JE et al.. Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium. 2019;59 :158-165. doi: 10.1016/j.canep.2019.01.022. PubMed PMID:30776582 PubMed Central PMC7098424.
  19. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
  20. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
  21. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  22. Lindberg, A, Talala, K, Kujala, P, Stenman, UH, Taari, K, Kilpeläinen, TP et al.. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. 2019;145 (3):632-638. doi: 10.1002/ijc.32129. PubMed PMID:30653262 .
  23. Schumacher, FR, Olama, AAA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2019;51 (2):363. doi: 10.1038/s41588-018-0330-6. PubMed PMID:30622367 .
  24. Deltour, I, Schlehofer, B, Massardier-Pilonchéry, A, Schlaefer, K, Armstrong, B, Giles, GG et al.. Exposure to loud noise and risk of vestibular schwannoma: results from the INTERPHONE international case‒control study. 2019;45 (2):183-193. doi: 10.5271/sjweh.3781. PubMed PMID:30614502 .
  25. Olsson, A, Bouaoun, L, Auvinen, A, Feychting, M, Johansen, C, Mathiesen, T et al.. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. 2019;141 (1):139-149. doi: 10.1007/s11060-018-03019-5. PubMed PMID:30421160 .
  26. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  27. Van Hemelrijck, M, Ji, X, Helleman, J, Roobol, MJ, van der Linden, W, Nieboer, D et al.. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. 2019;75 (3):523-531. doi: 10.1016/j.eururo.2018.10.025. PubMed PMID:30385049 .
  28. Li-Sheng Chen, S, Ching-Yuan Fann, J, Sipeky, C, Yang, TK, Yueh-Hsia Chiu, S, Ming-Fang Yen, A et al.. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. 2019;201 (3):486-495. doi: 10.1016/j.juro.2018.10.015. PubMed PMID:30366021 .
  29. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  30. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  31. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  32. Saarimäki, L, Hugosson, J, Tammela, TL, Carlsson, S, Talala, K, Auvinen, A et al.. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. 2019;5 (2):186-191. doi: 10.1016/j.euf.2017.07.007. PubMed PMID:28803925 PubMed Central PMC5809235.

Search PubMed

2018
  1. van der Kwast, TH, Helleman, J, Nieboer, D, Bruinsma, SM, Roobol, MJ, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium et al.. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. 2019;2 (3):333-336. doi: 10.1016/j.euo.2018.08.017. PubMed PMID:31200849 .
  2. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. ;52 (5-6):321-327. doi: 10.1080/21681805.2018.1559882. PubMed PMID:30698056 .
  3. Deltour, I, Schlehofer, B, Massardier-Pilonchéry, A, Schlaefer, K, Armstrong, B, Giles, GG et al.. Exposure to loud noise and risk of vestibular schwannoma: results from the INTERPHONE international case‒control study. 2019;45 (2):183-193. doi: 10.5271/sjweh.3781. PubMed PMID:30614502 .
  4. Olsson, A, Bouaoun, L, Auvinen, A, Feychting, M, Johansen, C, Mathiesen, T et al.. Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. 2019;141 (1):139-149. doi: 10.1007/s11060-018-03019-5. PubMed PMID:30421160 .
  5. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  6. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
  7. Van Hemelrijck, M, Ji, X, Helleman, J, Roobol, MJ, van der Linden, W, Nieboer, D et al.. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. 2019;75 (3):523-531. doi: 10.1016/j.eururo.2018.10.025. PubMed PMID:30385049 .
  8. Pöyhönen, A, Åkerla, J, Häkkinen, JT, Koskimäki, J, Tammela, TLJ, Auvinen, A et al.. Severity and bother of lower urinary tract symptoms among men aged 30-80 years: Tampere Ageing Male Urological Study (TAMUS). 2018;52 (4):296-301. doi: 10.1080/21681805.2018.1505944. PubMed PMID:30382800 .
  9. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  10. Niskanen, L, Partonen, T, Auvinen, A, Haukka, J. Excess mortality in Finnish diabetic subjects due to alcohol, accidents and suicide: a nationwide study. 2018;179 (5):299-306. doi: 10.1530/EJE-18-0351. PubMed PMID:30320503 .
  11. Togawa, K, Ahn, HS, Auvinen, A, Bauer, AJ, Brito, JP, Davies, L et al.. Long-term strategies for thyroid health monitoring after nuclear accidents: recommendations from an Expert Group convened by IARC. 2018;19 (10):1280-1283. doi: 10.1016/S1470-2045(18)30680-6. PubMed PMID:30303113 .
  12. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  13. Sipeky, C, Gao, P, Zhang, Q, Wang, L, Ettala, O, Talala, KM et al.. Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer. 2018;24 (24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. PubMed PMID:30181389 PubMed Central PMC6719560.
  14. Gao, P, Xia, JH, Sipeky, C, Dong, XM, Zhang, Q, Yang, Y et al.. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. 2018;174 (3):576-589.e18. doi: 10.1016/j.cell.2018.06.003. PubMed PMID:30033361 PubMed Central PMC6091222.
  15. Kaapu, KJ, Rantaniemi, L, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. 2018;8 (1):10308. doi: 10.1038/s41598-018-28541-4. PubMed PMID:29985440 PubMed Central PMC6037774.
  16. Hsu, CY, Yen, MF, Auvinen, A, Chiu, YH, Chen, HH. Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. 2018;27 (8):2519-2539. doi: 10.1177/0962280216682284. PubMed PMID:29984633 .
  17. Nikkilä, A, Raitanen, J, Lohi, O, Auvinen, A. Radiation exposure from computerized tomography and risk of childhood leukemia: Finnish register-based case-control study of childhood leukemia (FRECCLE). 2018;103 (11):1873-1880. doi: 10.3324/haematol.2018.187716. PubMed PMID:29976736 PubMed Central PMC6278981.
  18. Nikkilä, A, Kendall, G, Raitanen, J, Spycher, B, Lohi, O, Auvinen, A et al.. Effects of incomplete residential histories on studies of environmental exposure with application to childhood leukaemia and background radiation. 2018;166 :466-472. doi: 10.1016/j.envres.2018.06.035. PubMed PMID:29945121 .
  19. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
  20. Schumacher, FR, Al Olama, AA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2018;50 (7):928-936. doi: 10.1038/s41588-018-0142-8. PubMed PMID:29892016 PubMed Central PMC6568012.
  21. Ryödi, E, Metso, S, Huhtala, H, Välimäki, M, Auvinen, A, Jaatinen, P et al.. Cardiovascular Morbidity and Mortality After Treatment of Hyperthyroidism with Either Radioactive Iodine or Thyroidectomy. 2018;28 (9):1111-1120. doi: 10.1089/thy.2017.0461. PubMed PMID:29882483 .
  22. Barchuk, A, Bespalov, A, Huhtala, H, Chimed, T, Laricheva, I, Belyaev, A et al.. Breast and cervical cancer incidence and mortality trends in Russia 1980-2013. 2018;55 :73-80. doi: 10.1016/j.canep.2018.05.008. PubMed PMID:29843073 .
  23. Petridou, ET, Georgakis, MK, Erdmann, F, Ma, X, Heck, JE, Auvinen, A et al.. Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. 2018;33 (10):965-976. doi: 10.1007/s10654-018-0402-z. PubMed PMID:29761423 PubMed Central PMC6384148.
  24. Auvinen, A. Prostate cancer screening: what can we learn from randomised trials?. 2018;7 (1):12-17. doi: 10.21037/tau.2017.12.13. PubMed PMID:29594015 PubMed Central PMC5861281.
  25. Murtola, TJ, Vihervuori, VJ, Lahtela, J, Talala, K, Taari, K, Tammela, TL et al.. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2018;118 (9):1248-1254. doi: 10.1038/s41416-018-0055-4. PubMed PMID:29563633 PubMed Central PMC5943324.
  26. Booth, N, Rissanen, P, Tammela, TLJ, Taari, K, Talala, K, Auvinen, A et al.. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. 2018;93 :108-118. doi: 10.1016/j.ejca.2018.01.111. PubMed PMID:29501976 .
  27. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  28. Bruinsma, SM, Zhang, L, Roobol, MJ, Bangma, CH, Steyerberg, EW, Nieboer, D et al.. The Movember Foundation’s GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. 2018;121 (5):737-744. doi: 10.1111/bju.14106. PubMed PMID:29247473 .
  29. Neupane, S, Steyerberg, E, Raitanen, J, Talala, K, Pylväläinen, J, Taari, K et al.. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. 2018;25 (3):270-276. doi: 10.1111/iju.13508. PubMed PMID:29224236 .
  30. de Koning, HJ, Gulati, R, Moss, SM, Hugosson, J, Pinsky, PF, Berg, CD et al.. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. 2018;124 (6):1197-1206. doi: 10.1002/cncr.31178. PubMed PMID:29211316 PubMed Central PMC5839977.
  31. Toledano, MB, Auvinen, A, Tettamanti, G, Cao, Y, Feychting, M, Ahlbom, A et al.. An international prospective cohort study of mobile phone users and health (COSMOS): Factors affecting validity of self-reported mobile phone use. 2018;221 (1):1-8. doi: 10.1016/j.ijheh.2017.09.008. PubMed PMID:29056311 .
  32. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .

Search PubMed

2017
  1. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  2. Neupane, S, Steyerberg, E, Raitanen, J, Talala, K, Pylväläinen, J, Taari, K et al.. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. 2018;25 (3):270-276. doi: 10.1111/iju.13508. PubMed PMID:29224236 .
  3. de Koning, HJ, Gulati, R, Moss, SM, Hugosson, J, Pinsky, PF, Berg, CD et al.. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. 2018;124 (6):1197-1206. doi: 10.1002/cncr.31178. PubMed PMID:29211316 PubMed Central PMC5839977.
  4. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  5. Toledano, MB, Auvinen, A, Tettamanti, G, Cao, Y, Feychting, M, Ahlbom, A et al.. An international prospective cohort study of mobile phone users and health (COSMOS): Factors affecting validity of self-reported mobile phone use. 2018;221 (1):1-8. doi: 10.1016/j.ijheh.2017.09.008. PubMed PMID:29056311 .
  6. Vuorinen, RK, Mäenpää, MM, Nieminen, K, Tomás, EI, Luukkaala, TH, Auvinen, A et al.. Costs of Robotic-Assisted Versus Traditional Laparoscopy in Endometrial Cancer. 2017;27 (8):1788-1793. doi: 10.1097/IGC.0000000000001073. PubMed PMID:28937446 .
  7. Tsodikov, A, Gulati, R, Heijnsdijk, EAM, Pinsky, PF, Moss, SM, Qiu, S et al.. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. 2017;167 (7):449-455. doi: 10.7326/M16-2586. PubMed PMID:28869989 PubMed Central PMC5734053.
  8. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;17 (1):585. doi: 10.1186/s12885-017-3579-8. PubMed PMID:28851310 PubMed Central PMC5575900.
  9. Haukka, J, Niskanen, L, Auvinen, A. Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin. 2017;141 (12):2437-2449. doi: 10.1002/ijc.31016. PubMed PMID:28840596 .
  10. Saarimäki, L, Hugosson, J, Tammela, TL, Carlsson, S, Talala, K, Auvinen, A et al.. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. 2019;5 (2):186-191. doi: 10.1016/j.euf.2017.07.007. PubMed PMID:28803925 PubMed Central PMC5809235.
  11. Auvinen, A, Rannikko, A, Taari, K, Kujala, P, Mirtti, T, Kenttämies, A et al.. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. 2017;32 (6):521-527. doi: 10.1007/s10654-017-0292-5. PubMed PMID:28762124 .
  12. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .
  13. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  14. But, A, De Bruin, ML, Bazelier, MT, Hjellvik, V, Andersen, M, Auvinen, A et al.. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. 2017;60 (9):1691-1703. doi: 10.1007/s00125-017-4312-5. PubMed PMID:28573394 PubMed Central PMC5552833.
  15. Talibov, M, Auvinen, A, Weiderpass, E, Hansen, J, Martinsen, JI, Kjaerheim, K et al.. Occupational solvent exposure and adult chronic lymphocytic leukemia: No risk in a population-based case-control study in four Nordic countries. 2017;141 (6):1140-1147. doi: 10.1002/ijc.30814. PubMed PMID:28571111 .
  16. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. 2017;77 (9):1029-1035. doi: 10.1002/pros.23359. PubMed PMID:28480542 .
  17. Bruinsma, SM, Roobol, MJ, Carroll, PR, Klotz, L, Pickles, T, Moore, CM et al.. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer – results of a modified Delphi consensus procedure. 2017;14 (5):312-322. doi: 10.1038/nrurol.2017.26. PubMed PMID:28290462 .
  18. Talibov, M, Salmelin, R, Lehtinen-Jacks, S, Auvinen, A. Estimation of occupational cosmic radiation exposure among airline personnel: Agreement between a job-exposure matrix, aggregate, and individual dose estimates. 2017;60 (4):386-393. doi: 10.1002/ajim.22705. PubMed PMID:28262960 .
  19. Murtola, TJ, Virkku, A, Talala, K, Stenman, UH, Taari, K, Tammela, TLJ et al.. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. 2017;198 (2):305-309. doi: 10.1016/j.juro.2017.02.069. PubMed PMID:28216328 .
  20. Artama, M, Braumann, J, Raitanen, J, Uotila, J, Gissler, M, Isojärvi, J et al.. Women treated for epilepsy during pregnancy: outcomes from a nationwide population-based cohort study. 2017;96 (7):812-820. doi: 10.1111/aogs.13109. PubMed PMID:28176327 .
  21. Kilpeläinen, TP, Pogodin-Hannolainen, D, Kemppainen, K, Talala, K, Raitanen, J, Taari, K et al.. Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;198 (1):50-57. doi: 10.1016/j.juro.2017.01.048. PubMed PMID:28104375 .
  22. Haring, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;51 (1):5-12. doi: 10.1080/21681805.2016.1271353. PubMed PMID:28084175 .
  23. Bronsveld, HK, Jensen, V, Vahl, P, De Bruin, ML, Cornelissen, S, Sanders, J et al.. Diabetes and Breast Cancer Subtypes. 2017;12 (1):e0170084. doi: 10.1371/journal.pone.0170084. PubMed PMID:28076434 PubMed Central PMC5226802.
  24. Nevalainen, J, Stenman, UH, Tammela, TL, Roobol, M, Carlsson, S, Talala, K et al.. What explains the differences between centres in the European screening trial? A simulation study. 2017;46 :14-19. doi: 10.1016/j.canep.2016.11.005. PubMed PMID:27889661 PubMed Central PMC5415347.
  25. Walter, SD, de Koning, HJ, Hugosson, J, Talala, K, Roobol, MJ, Carlsson, S et al.. Impact of cause of death adjudication on the results of the European prostate cancer screening trial. 2017;116 (1):141-148. doi: 10.1038/bjc.2016.378. PubMed PMID:27855442 PubMed Central PMC5220145.
  26. Neupane, S, Bray, F, Auvinen, A. National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. 2017;35 (6):851-858. doi: 10.1007/s00345-016-1953-9. PubMed PMID:27744614 .

Search PubMed

2016
  1. Hsu, CY, Yen, MF, Auvinen, A, Chiu, YH, Chen, HH. Bayesian negative-binomial-family-based multistate Markov model for the evaluation of periodic population-based cancer screening considering incomplete information and measurement errors. 2018;27 (8):2519-2539. doi: 10.1177/0962280216682284. PubMed PMID:29984633 .
  2. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  3. Nevalainen, J, Stenman, UH, Tammela, TL, Roobol, M, Carlsson, S, Talala, K et al.. What explains the differences between centres in the European screening trial? A simulation study. 2017;46 :14-19. doi: 10.1016/j.canep.2016.11.005. PubMed PMID:27889661 PubMed Central PMC5415347.
  4. Walter, SD, de Koning, HJ, Hugosson, J, Talala, K, Roobol, MJ, Carlsson, S et al.. Impact of cause of death adjudication on the results of the European prostate cancer screening trial. 2017;116 (1):141-148. doi: 10.1038/bjc.2016.378. PubMed PMID:27855442 PubMed Central PMC5220145.
  5. Grell, K, Frederiksen, K, Schüz, J, Cardis, E, Armstrong, B, Siemiatycki, J et al.. The Intracranial Distribution of Gliomas in Relation to Exposure From Mobile Phones: Analyses From the INTERPHONE Study. 2016;184 (11):818-828. doi: 10.1093/aje/kww082. PubMed PMID:27810856 PubMed Central PMC5152665.
  6. Kinnunen, PT, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;50 (6):413-419. doi: 10.1080/21681805.2016.1228085. PubMed PMID:27628763 .
  7. Kilpeläinen, TP, Talala, K, Raitanen, J, Taari, K, Kujala, P, Tammela, TLJ et al.. Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;184 (10):720-731. doi: 10.1093/aje/kww084. PubMed PMID:27777219 .
  8. Carlsson, SV, de Carvalho, TM, Roobol, MJ, Hugosson, J, Auvinen, A, Kwiatkowski, M et al.. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. 2016;122 (21):3386-3393. doi: 10.1002/cncr.30192. PubMed PMID:27459245 PubMed Central PMC5073010.
  9. Kaapu, KJ, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;115 (11):1289-1295. doi: 10.1038/bjc.2016.328. PubMed PMID:27755533 PubMed Central PMC5129833.
  10. Bokhorst, LP, Zappa, M, Carlsson, SV, Kwiatkowski, M, Denis, L, Paez, A et al.. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). 2016;118 (5):677-680. doi: 10.1111/bju.13505. PubMed PMID:27104278 PubMed Central PMC5072450.
  11. Neupane, S, Bray, F, Auvinen, A. National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis. 2017;35 (6):851-858. doi: 10.1007/s00345-016-1953-9. PubMed PMID:27744614 .
  12. Kilpeläinen, TP, Mäkinen, T, Karhunen, PJ, Aro, J, Lahtela, J, Taari, K et al.. Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;45 :1-5. doi: 10.1016/j.canep.2016.08.022. PubMed PMID:27636505 .
  13. Nikkilä, A, Erme, S, Arvela, H, Holmgren, O, Raitanen, J, Lohi, O et al.. Background radiation and childhood leukemia: A nationwide register-based case-control study. 2016;139 (9):1975-82. doi: 10.1002/ijc.30264. PubMed PMID:27405274 .
  14. Pöyhönen, A, Auvinen, A, Häkkinen, JT, Koskimäki, J, Tammela, TL. Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men. 2016;95 :164-70. doi: 10.1016/j.urology.2016.06.023. PubMed PMID:27349526 .
  15. Auvinen, A. Prostate cancer: Prudent practice optimizes screening outcomes. 2016;13 (7):376-7. doi: 10.1038/nrurol.2016.90. PubMed PMID:27215425 .
  16. Pakarainen, T, Raitanen, J, Talala, K, Taari, K, Kujala, P, Tammela, TL et al.. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. 2016;70 (3):499-505. doi: 10.1016/j.eururo.2016.05.009. PubMed PMID:27210461 .
  17. Peeters, PJ, Bazelier, MT, Leufkens, HG, Auvinen, A, van Staa, TP, de Vries, F et al.. Insulin glargine use and breast cancer risk: Associations with cumulative exposure. 2016;55 (7):851-8. doi: 10.3109/0284186X.2016.1155736. PubMed PMID:27150973 PubMed Central PMC4975082.
  18. Veitonmäki, T, Murtola, TJ, Talala, K, Taari, K, Tammela, T, Auvinen, A et al.. Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. 2016;11 (4):e0153413. doi: 10.1371/journal.pone.0153413. PubMed PMID:27100876 PubMed Central PMC4839624.
  19. Gusev, A, Shi, H, Kichaev, G, Pomerantz, M, Li, F, Long, HW et al.. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. 2016;7 :10979. doi: 10.1038/ncomms10979. PubMed PMID:27052111 PubMed Central PMC4829663.
  20. Salminen, JK, Tammela, TL, Auvinen, A, Murtola, TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. 2016;27 (5):637-45. doi: 10.1007/s10552-016-0737-2. PubMed PMID:27038166 .
  21. Sarre, S, Määttänen, L, Tammela, TL, Auvinen, A, Murtola, TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. 2016;50 (4):267-73. doi: 10.3109/21681805.2016.1145734. PubMed PMID:26927237 .
  22. Pesonen, JS, Cartwright, R, Mangera, A, Santti, H, Griebling, TL, Pryalukhin, AE et al.. Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. 2016;70 (2):372-81. doi: 10.1016/j.eururo.2016.02.014. PubMed PMID:26905787 .
  23. Wakeford, R, Auvinen, A, Gent, RN, Jacob, P, Kesminiene, A, Laurier, D et al.. Re: Thyroid Cancer Among Young People in Fukushima. 2016;27 (3):e20-1. doi: 10.1097/EDE.0000000000000466. PubMed PMID:26841059 .
  24. Järvelä, L, Raitanen, J, Erme, S, Lohi, O, Auvinen, A. Residential mobility and the risk of childhood leukemia. 2016;27 (3):433-43. doi: 10.1007/s10552-016-0720-y. PubMed PMID:26830898 .
  25. Murtola, TJ, Karppa, EK, Taari, K, Talala, K, Tammela, TL, Auvinen, A et al.. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. 2016;138 (12):2820-8. doi: 10.1002/ijc.30017. PubMed PMID:26804670 .
  26. Lehtinen, P, Pasanen, K, Kolho, KL, Auvinen, A. Incidence of Pediatric Inflammatory Bowel Disease in Finland: An Environmental Study. 2016;63 (1):65-70. doi: 10.1097/MPG.0000000000001050. PubMed PMID:26636498 .
  27. Nevalainen, O, Simola, M, Ansakorpi, H, Raitanen, J, Artama, M, Isojärvi, J et al.. Epilepsy, excess deaths and years of life lost from external causes. 2016;31 (5):445-53. doi: 10.1007/s10654-015-0095-5. PubMed PMID:26520637 .
  28. Auvinen, A, Moss, SM, Tammela, TL, Taari, K, Roobol, MJ, Schröder, FH et al.. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. 2016;22 (1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. PubMed PMID:26289069 PubMed Central PMC4951205.

Search PubMed

2015
  1. Nevalainen, O, Simola, M, Ansakorpi, H, Raitanen, J, Artama, M, Isojärvi, J et al.. Epilepsy, excess deaths and years of life lost from external causes. 2016;31 (5):445-53. doi: 10.1007/s10654-015-0095-5. PubMed PMID:26520637 .
  2. Rahu, K, Rahu, M, Tekkel, M, Veidebaum, T, Hakulinen, T, Auvinen, A et al.. Chernobyl cleanup workers from Estonia: cohort description and related epidemiological research. 2015;35 (4):R35-45. doi: 10.1088/0952-4746/35/4/R35. PubMed PMID:26512763 .
  3. Auvinen, A. [How do I write a scientific article–advice to a young researcher]. 2015;131 (16):1460-6. . PubMed PMID:26485939 .
  4. Friis, S, Kesminiene, A, Espina, C, Auvinen, A, Straif, K, Schüz, J et al.. European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. 2015;39 Suppl 1 :S107-19. doi: 10.1016/j.canep.2015.08.003. PubMed PMID:26390952 .
  5. Davies, NM, Gaunt, TR, Lewis, SJ, Holly, J, Donovan, JL, Hamdy, FC et al.. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. 2015;26 (11):1603-16. doi: 10.1007/s10552-015-0654-9. PubMed PMID:26387087 PubMed Central PMC4596899.
  6. Pashayan, N, Pharoah, PD, Schleutker, J, Talala, K, Tammela, TLj, Määttänen, L et al.. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. 2015;113 (7):1086-93. doi: 10.1038/bjc.2015.289. PubMed PMID:26291059 PubMed Central PMC4651137.
  7. Auvinen, A, Moss, SM, Tammela, TL, Taari, K, Roobol, MJ, Schröder, FH et al.. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. 2016;22 (1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. PubMed PMID:26289069 PubMed Central PMC4951205.
  8. Ryödi, E, Metso, S, Jaatinen, P, Huhtala, H, Saaristo, R, Välimäki, M et al.. Cancer Incidence and Mortality in Patients Treated Either With RAI or Thyroidectomy for Hyperthyroidism. 2015;100 (10):3710-7. doi: 10.1210/jc.2015-1874. PubMed PMID:26262435 .
  9. Eloranta, K, Auvinen, A. Population attitudes towards research use of health care registries: a population-based survey in Finland. 2015;16 :48. doi: 10.1186/s12910-015-0040-x. PubMed PMID:26183438 PubMed Central PMC4504396.
  10. Szulkin, R, Whitington, T, Eklund, M, Aly, M, Eeles, RA, Easton, D et al.. Prediction of individual genetic risk to prostate cancer using a polygenic score. 2015;75 (13):1467-74. doi: 10.1002/pros.23037. PubMed PMID:26177737 .
  11. Schüz, J, Espina, C, Villain, P, Herrero, R, Leon, ME, Minozzi, S et al.. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. 2015;39 Suppl 1 :S1-10. doi: 10.1016/j.canep.2015.05.009. PubMed PMID:26164654 .
  12. McColl, N, Auvinen, A, Kesminiene, A, Espina, C, Erdmann, F, de Vries, E et al.. European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer. 2015;39 Suppl 1 :S93-100. doi: 10.1016/j.canep.2015.03.016. PubMed PMID:26126928 .
  13. Nevalainen, OP, Ansakorpi, H, Auvinen, A. Epilepsy-related clinical characteristics and mortality: a systematic review and meta-analysis. 2015;84 (17):1823-4. . PubMed PMID:26106661 .
  14. Greinert, R, de Vries, E, Erdmann, F, Espina, C, Auvinen, A, Kesminiene, A et al.. European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. 2015;39 Suppl 1 :S75-83. doi: 10.1016/j.canep.2014.12.014. PubMed PMID:26096748 .
  15. Veitonmäki, T, Murtola, TJ, Määttänen, L, Taari, K, Stenman, UH, Tammela, TL et al.. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. 2015;75 (13):1394-402. doi: 10.1002/pros.23020. PubMed PMID:26073992 .
  16. Kreuzer, M, Auvinen, A, Cardis, E, Hall, J, Jourdain, JR, Laurier, D et al.. Low-dose ionising radiation and cardiovascular diseases–Strategies for molecular epidemiological studies in Europe. ;764 :90-100. doi: 10.1016/j.mrrev.2015.03.002. PubMed PMID:26041268 .
  17. Amin Al Olama, A, Dadaev, T, Hazelett, DJ, Li, Q, Leongamornlert, D, Saunders, EJ et al.. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. 2015;24 (19):5589-602. doi: 10.1093/hmg/ddv203. PubMed PMID:26025378 PubMed Central PMC4572072.
  18. Shrestha, M, Raitanen, J, Salminen, T, Lahkola, A, Auvinen, A. Pituitary tumor risk in relation to mobile phone use: A case-control study. 2015;54 (8):1159-65. doi: 10.3109/0284186X.2015.1045624. PubMed PMID:25982941 .
  19. Schröder, F, Hugosson, J, Carlsson, S, Moss, S, Roobol, M, Auvinen, A et al.. Prostate cancer screening in Europe – Authors’ reply. 2015;385 (9977):1507-8. doi: 10.1016/S0140-6736(15)60749-8. PubMed PMID:25933276 .
  20. Auvinen, A, Kivelä, T, Heinävaara, S, Mrena, S. Eye Lens Opacities Among Physicians Occupationally Exposed to Ionizing Radiation. 2015;59 (7):945-8. doi: 10.1093/annhyg/mev022. PubMed PMID:25868644 .
  21. Amin Al Olama, A, Benlloch, S, Antoniou, AC, Giles, GG, Severi, G, Neal, DE et al.. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. 2015;24 (7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. PubMed PMID:25837820 PubMed Central PMC4491026.
  22. Murtola, TJ, Wahlfors, T, Haring, A, Taari, K, Stenman, UH, Tammela, TL et al.. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. 2015;68 (6):1089-97. doi: 10.1016/j.eururo.2015.03.026. PubMed PMID:25819720 .
  23. Buzzoni, C, Auvinen, A, Roobol, MJ, Carlsson, S, Moss, SM, Puliti, D et al.. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. 2015;68 (5):885-90. doi: 10.1016/j.eururo.2015.02.042. PubMed PMID:25791513 PubMed Central PMC4982869.
  24. Stegeman, S, Amankwah, E, Klein, K, O’Mara, TA, Kim, D, Lin, HY et al.. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. 2015;5 (4):368-79. doi: 10.1158/2159-8290.CD-14-1057. PubMed PMID:25691096 PubMed Central PMC4390388.
  25. Yen, AM, Auvinen, A, Schleutker, J, Wu, YY, Fann, JC, Tammela, T et al.. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants. 2015;75 (8):825-35. doi: 10.1002/pros.22964. PubMed PMID:25683204 .
  26. Kaapu, KJ, Ahti, J, Tammela, TL, Auvinen, A, Murtola, TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. 2015;137 (5):1187-95. doi: 10.1002/ijc.29470. PubMed PMID:25656312 .
  27. Kilpeläinen, TP, Tammela, TL, Malila, N, Hakama, M, Santti, H, Määttänen, L et al.. The Finnish prostate cancer screening trial: analyses on the screening failures. 2015;136 (10):2437-43. doi: 10.1002/ijc.29300. PubMed PMID:25359457 .
  28. Saarimäki, L, Tammela, TL, Määttänen, L, Taari, K, Kujala, PM, Raitanen, J et al.. Family history in the Finnish Prostate Cancer Screening Trial. 2015;136 (9):2172-7. doi: 10.1002/ijc.29243. PubMed PMID:25274038 .

Search PubMed

Bova Group

PELICAN-Personalized Cancer Medicine

ORCID 0000-0003-1639-3104

https://scholar.google.com/citations?user=7S0lp5MAAAAJ&hl=en

Woodcock DJ, Riabchenko E, Taavitsainen S, Kankainen M, Gundem G, Brewer DS, Ellonen P, Lepistö M, Golubeva YG, Warner AC, Tolonen TT, Jasu J, Isaacs WB, Emmert-Buck MR, Nykter M, Visakorpi T, Bova GS, Wedge DC. Prostate cancer evolution from multilineage primary to single lineage metastasis in ten men with implications for liquid biopsy. Nat Commun. 2020 Oct 8;11(1):5070. PMID: 33033260.

ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020 Feb;578(7793):82-93. PMID: 32025007;

Sainio M, Visakorpi T, Tolonen T, Ilvesaro J, Bova GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. Pathol Res Pract. 2018 Apr 26. pii: 0344-0338(18)30003-7. PMID: 29728311.

Högnäs G, Kivinummi K, Kallio HML, Hieta R, Ruusuvuori P, Koskenalho A, Kesseli J, Tammela TLJ, Riikonen J, Ilvesaro J, Kares S, Hirvikoski PP, Laurila M, Mirtti T, Nykter M, Kujala PM, Visakorpi T, Tolonen T, Bova GS. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. Am J Surg Pathol. 2018 Jan;42(1):103-115. PMID: 28984675.

Bova GS, Cancer Genomics: Human metastases under scrutiny. Nature, 2017 548(7667):287-288.  PMID: 28783720

Behjati S, Gundem G, Wedge DC, Roberts ND, Tarpey PS, Cooke SL, Van Loo P, Alexandrov LB, Ramakrishna M, Davies H, Nik-Zainal S, Hardy C, Latimer C, Raine KM, Stebbings L, Menzies A, Jones D, Shepherd R, Butler AP, Teague JW, Jorgensen M, Khatri B, Pillay N, Shlien A, Futreal PA, Badie C; ICGC Prostate Group, McDermott U, Bova GS, Richardson AL, Flanagan AM, Stratton MR, Campbell PJ. Mutational signatures of ionizing radiation in second malignancies. Nat Commun. 2016 Sep 12;7:12605. PMID: 27615322

Bova GS, Kallio HML, Annala M, Kivinummi K, Högnäs G, Häyrynen S, Rantapero T, Kivinen V, Isaacs WB, Tolonen T, Nykter M, Visakorpi T. Integrated clinical, whole genome, and transcriptome analysis of multisampled lethal prostate cancer. Cold Spring Harbor Molecular Case Studies. 2016 May 2(3). PMID: 27148588.

Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, Neal DE, Cooper CS,Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, and Bova GS. The Evolutionary History of Lethal Metastatic Prostate Cancer. Nature, 520, 353-7, 2015. PMID: 25830880

Tubio JM, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O’Meara S, Anderson E, Maddison M, Gamble S; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van’t Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ. Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. 2014 Aug 1;345(6196):1251343. PMID: 25082706

Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, Nelson WG, Yegnasubramanian S, Luo J, Wang Y, Xu J, Isaacs WB, Visakorpi T, Bova GS. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer. Nature Medicine 2009; 15: 560-565.  PMID:19363497

Emmert-Streib Group

Predictive Society and Data Analytics Lab

 

2020
  1. Manjang, K, Tripathi, S, Yli-Harja, O, Dehmer, M, Emmert-Streib, F. Graph-based exploitation of gene ontology using GOxploreR for scrutinizing biological significance. Sci Rep. 2020;10 (1):16672. doi: 10.1038/s41598-020-73326-3. PubMed PMID:33028846 .
  2. Perera, N, Dehmer, M, Emmert-Streib, F. Named Entity Recognition and Relation Detection for Biomedical Information Extraction. 2020;8 :673. doi: 10.3389/fcell.2020.00673. PubMed PMID:32984300 PubMed Central PMC7485218.
  3. Doan, P, Musa, A, Murugesan, A, Sipilä, V, Candeias, NR, Emmert-Streib, F et al.. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells. 2020;9 (3):. doi: 10.3390/cells9030681. PubMed PMID:32164385 PubMed Central PMC7140667.
  4. Yang, Z, Dehmer, M, Yli-Harja, O, Emmert-Streib, F. Combining deep learning with token selection for patient phenotyping from electronic health records. 2020;10 (1):1432. doi: 10.1038/s41598-020-58178-1. PubMed PMID:31996705 PubMed Central PMC6989657.

Search PubMed

2019
  1. Emmert-Streib, F, Dehmer, M, Yli-Harja, O. Ensuring Quality Standards and Reproducible Research for Data Analysis Services in Oncology: A Cooperative Service Model. 2019;7 :349. doi: 10.3389/fcell.2019.00349. PubMed PMID:31921859 PubMed Central PMC6929679.
  2. Emmert-Streib, F, Yli-Harja, O, Dehmer, M. Utilizing Social Media Data for Psychoanalysis to Study Human Personality. 2019;10 :2596. doi: 10.3389/fpsyg.2019.02596. PubMed PMID:31803123 PubMed Central PMC6873989.
  3. Smolander, J, Stupnikov, A, Glazko, G, Dehmer, M, Emmert-Streib, F. Comparing biological information contained in mRNA and non-coding RNAs for classification of lung cancer patients. 2019;19 (1):1176. doi: 10.1186/s12885-019-6338-1. PubMed PMID:31796020 PubMed Central PMC6892207.
  4. Dehmer, M, Chen, Z, Emmert-Streib, F, Tripathi, S, Mowshowitz, A, Levitchi, A et al.. Measuring the complexity of directed graphs: A polynomial-based approach. 2019;14 (11):e0223745. doi: 10.1371/journal.pone.0223745. PubMed PMID:31725742 PubMed Central PMC6855486.
  5. Emmert-Streib, F, Moutari, S, Dehmer, M. A comprehensive survey of error measures for evaluating binary decision making in data science. ;9 (5):e1303. doi: 10.1002/widm.1303. PubMed PMID:31656552 PubMed Central PMC6777486.
  6. Glazko, G, Zybailov, B, Emmert-Streib, F, Baranova, A, Rahmatallah, Y. Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study. 2019;14 (8):e0221444. doi: 10.1371/journal.pone.0221444. PubMed PMID:31437237 PubMed Central PMC6705791.
  7. Musa, A, Tripathi, S, Dehmer, M, Emmert-Streib, F. L1000 Viewer: A Search Engine and Web Interface for the LINCS Data Repository. 2019;10 :557. doi: 10.3389/fgene.2019.00557. PubMed PMID:31258549 PubMed Central PMC6588157.
  8. Musa, A, Tripathi, S, Dehmer, M, Yli-Harja, O, Kauffman, SA, Emmert-Streib, F et al.. Systems Pharmacogenomic Landscape of Drug Similarities from LINCS data: Drug Association Networks. 2019;9 (1):7849. doi: 10.1038/s41598-019-44291-3. PubMed PMID:31127155 PubMed Central PMC6534546.
  9. Smolander, J, Dehmer, M, Emmert-Streib, F. Comparing deep belief networks with support vector machines for classifying gene expression data from complex disorders. 2019;9 (7):1232-1248. doi: 10.1002/2211-5463.12652. PubMed PMID:31074948 PubMed Central PMC6609581.
  10. Moore, D, Simoes, RM, Dehmer, M, Emmert-Streib, F. Prostate Cancer Gene Regulatory Network Inferred from RNA-Seq Data. 2019;20 (1):38-48. doi: 10.2174/1389202919666181107122005. PubMed PMID:31015790 PubMed Central PMC6446481.
  11. Doan, P, Musa, A, Candeias, NR, Emmert-Streib, F, Yli-Harja, O, Kandhavelu, M et al.. Alkylaminophenol Induces G1/S Phase Cell Cycle Arrest in Glioblastoma Cells Through p53 and Cyclin-Dependent Kinase Signaling Pathway. 2019;10 :330. doi: 10.3389/fphar.2019.00330. PubMed PMID:31001122 PubMed Central PMC6454069.
  12. Azam, MF, Musa, A, Dehmer, M, Yli-Harja, OP, Emmert-Streib, F. Global Genetics Research in Prostate Cancer: A Text Mining and Computational Network Theory Approach. 2019;10 :70. doi: 10.3389/fgene.2019.00070. PubMed PMID:30838019 PubMed Central PMC6383410.
  13. Viswanathan, A, Kute, D, Musa, A, Konda Mani, S, Sipilä, V, Emmert-Streib, F et al.. 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. 2019;166 :291-303. doi: 10.1016/j.ejmech.2019.01.021. PubMed PMID:30731398 .

Search PubMed

2018
  1. Stupnikov, A, O’Reilly, PG, McInerney, CE, Roddy, AC, Dunne, PD, Gilmore, A et al.. Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression. 2018;2 :. doi: 10.1200/PO.18.00014. PubMed PMID:30324181 PubMed Central PMC6186166.
  2. Musa, A, Tripathi, S, Kandhavelu, M, Dehmer, M, Emmert-Streib, F. Harnessing the biological complexity of Big Data from LINCS gene expression signatures. 2018;13 (8):e0201937. doi: 10.1371/journal.pone.0201937. PubMed PMID:30157183 PubMed Central PMC6114505.
  3. Baltakys, K, Kanniainen, J, Emmert-Streib, F. Multilayer Aggregation with Statistical Validation: Application to Investor Networks. 2018;8 (1):8198. doi: 10.1038/s41598-018-26575-2. PubMed PMID:29844512 PubMed Central PMC5974194.
  4. Musa, A, Ghoraie, LS, Zhang, SD, Glazko, G, Yli-Harja, O, Dehmer, M et al.. A review of connectivity map and computational approaches in pharmacogenomics. 2018;19 (3):506-523. doi: 10.1093/bib/bbw112. PubMed PMID:28069634 PubMed Central PMC5952941.

Search PubMed

2017
  1. Emmert-Streib, F, Dehmer, M, Yli-Harja, O. Lessons from the Human Genome Project: Modesty, Honesty, and Realism. 2017;8 :184. doi: 10.3389/fgene.2017.00184. PubMed PMID:29218057 PubMed Central PMC5703740.
  2. Glazko, G, Rahmatallah, Y, Zybailov, B, Emmert-Streib, F. Extracting the Strongest Signals from Omics Data: Differentially Expressed Pathways and Beyond. 2017;1613 :125-159. doi: 10.1007/978-1-4939-7027-8_7. PubMed PMID:28849561 PubMed Central PMC5846121.
  3. Tripathi, S, Lloyd-Price, J, Ribeiro, A, Yli-Harja, O, Dehmer, M, Emmert-Streib, F et al.. sgnesR: An R package for simulating gene expression data from an underlying real gene network structure considering delay parameters. 2017;18 (1):325. doi: 10.1186/s12859-017-1731-8. PubMed PMID:28676075 PubMed Central PMC5496254.
  4. Musa, A, Ghoraie, LS, Zhang, SD, Glazko, G, Yli-Harja, O, Dehmer, M et al.. A review of connectivity map and computational approaches in pharmacogenomics. 2017;18 (5):903. doi: 10.1093/bib/bbx023. PubMed PMID:28334173 PubMed Central PMC6113891.
  5. Rahmatallah, Y, Zybailov, B, Emmert-Streib, F, Glazko, G. GSAR: Bioconductor package for Gene Set analysis in R. 2017;18 (1):61. doi: 10.1186/s12859-017-1482-6. PubMed PMID:28118818 PubMed Central PMC5259853.

Search PubMed

2016
  1. Stupnikov, A, Tripathi, S, de Matos Simoes, R, McArt, D, Salto-Tellez, M, Glazko, G et al.. samExploreR: exploring reproducibility and robustness of RNA-seq results based on SAM files. 2016;32 (21):3345-3347. doi: 10.1093/bioinformatics/btw475. PubMed PMID:27402900 .
  2. Emmert-Streib, F, Dehmer, M, Yli-Harja, O. Against Dataism and for Data Sharing of Big Biomedical and Clinical Data with Research Parasites. 2016;7 :154. doi: 10.3389/fgene.2016.00154. PubMed PMID:27630666 PubMed Central PMC5005320.
  3. Emmert-Streib, F, Tuomisto, L, Yli-Harja, O. The Need for Formally Defining “Modern Medicine” by Means of Experimental Design. 2016;7 :60. doi: 10.3389/fgene.2016.00060. PubMed PMID:27148357 PubMed Central PMC4837140.
  4. Tripathi, S, Moutari, S, Dehmer, M, Emmert-Streib, F. Comparison of module detection algorithms in protein networks and investigation of the biological meaning of predicted modules. 2016;17 :129. doi: 10.1186/s12859-016-0979-8. PubMed PMID:26987731 PubMed Central PMC4797184.
  5. Buckley, NE, Haddock, P, De Matos Simoes, R, Parkes, E, Irwin, G, Emmert-Streib, F et al.. A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer. 2016;7 (15):19884-96. doi: 10.18632/oncotarget.7865. PubMed PMID:26943587 PubMed Central PMC4991425.
  6. Emmert-Streib, F, Moutari, S, Dehmer, M. The Process of Analyzing Data is the Emergent Feature of Data Science. 2016;7 :12. doi: 10.3389/fgene.2016.00012. PubMed PMID:26904100 PubMed Central PMC4746257.
  7. Rahmatallah, Y, Emmert-Streib, F, Glazko, G. Gene set analysis approaches for RNA-seq data: performance evaluation and application guideline. 2016;17 (3):393-407. doi: 10.1093/bib/bbv069. PubMed PMID:26342128 PubMed Central PMC4870397.

Search PubMed

2015
  1. Emmert-Streib, F, Dehmer, M. Biological networks: the microscope of the twenty-first century?. 2015;6 :307. doi: 10.3389/fgene.2015.00307. PubMed PMID:26528327 PubMed Central PMC4602153.
  2. Olsen, C, Fleming, K, Prendergast, N, Rubio, R, Emmert-Streib, F, Bontempi, G et al.. Using shRNA experiments to validate gene regulatory networks. 2015;4 :123-6. doi: 10.1016/j.gdata.2015.03.011. PubMed PMID:26484195 PubMed Central PMC4535466.
  3. Dehmer, M, Emmert-Streib, F, Shi, Y, Stefu, M, Tripathi, S. Discrimination Power of Polynomial-Based Descriptors for Graphs by Using Functional Matrices. 2015;10 (10):e0139265. doi: 10.1371/journal.pone.0139265. PubMed PMID:26479495 PubMed Central PMC4610680.
  4. Rahmatallah, Y, Emmert-Streib, F, Glazko, G. Gene set analysis approaches for RNA-seq data: performance evaluation and application guideline. 2016;17 (3):393-407. doi: 10.1093/bib/bbv069. PubMed PMID:26342128 PubMed Central PMC4870397.
  5. Alvi, MA, McArt, DG, Kelly, P, Fuchs, MA, Alderdice, M, McCabe, CM et al.. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. 2015;6 (25):20863-74. doi: 10.18632/oncotarget.4576. PubMed PMID:26315110 PubMed Central PMC4673235.
  6. Stupnikov, A, Glazko, GV, Emmert-Streib, F. Effects of subsampling on characteristics of RNA-seq data from triple-negative breast cancer patients. 2015;34 (10):427-38. doi: 10.1186/s40880-015-0040-8. PubMed PMID:26253000 PubMed Central PMC4593382.
  7. Dehmer, M, Kurt, Z, Emmert-Streib, F, Them, C, Schulc, E, Hofer, S et al.. Structural Analysis of Treatment Cycles Representing Transitions between Nursing Organizational Units Inferred from Diabetes. 2015;10 (6):e0127152. doi: 10.1371/journal.pone.0127152. PubMed PMID:26030296 PubMed Central PMC4452654.
  8. de Matos Simoes, R, Dalleau, S, Williamson, KE, Emmert-Streib, F. Urothelial cancer gene regulatory networks inferred from large-scale RNAseq, Bead and Oligo gene expression data. 2015;9 :21. doi: 10.1186/s12918-015-0165-z. PubMed PMID:25971253 PubMed Central PMC4460634.
  9. Emmert-Streib, F, Zhang, SD, Hamilton, P. Computational cancer biology: education is a natural key to many locks. 2015;15 :7. doi: 10.1186/s12885-014-1002-2. PubMed PMID:25588624 PubMed Central PMC4298945.

Search PubMed

Granberg Group

Cancer Regulation and Immunology

 

2020
  1. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. 2020;38 (3):424-428. doi: 10.1016/j.ccell.2020.08.019. PubMed PMID:32931743 .
  2. Yang, M, Petralia, F, Li, Z, Li, H, Ma, W, Song, X et al.. Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and Transcriptomics. 2020;11 (2):186-195.e9. doi: 10.1016/j.cels.2020.06.013. PubMed PMID:32710834 .
  3. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. 2020;38 (3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. PubMed PMID:32649887 .
  4. Doan, P, Musa, A, Murugesan, A, Sipilä, V, Candeias, NR, Emmert-Streib, F et al.. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells. 2020;9 (3):. doi: 10.3390/cells9030681. PubMed PMID:32164385 PubMed Central PMC7140667.
  5. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .

Search PubMed

2019

Search PubMed

2018
  1. Luoto, S, Hermelo, I, Vuorinen, EM, Hannus, P, Kesseli, J, Nykter, M et al.. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma. 2018;78 (19):5574-5585. doi: 10.1158/0008-5472.CAN-17-3714. PubMed PMID:29921698 .
  2. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Erratum: Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. 2018;4 (3):. doi: 10.1101/mcs.a003129. PubMed PMID:29858379 PubMed Central PMC5983177.
  3. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. 2018;4 (2):. doi: 10.1101/mcs.a002246. PubMed PMID:29602769 PubMed Central PMC5880256.
  4. Haapasalo, J, Nordfors, K, Granberg, KJ, Kivioja, T, Nykter, M, Haapasalo, H et al.. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas. 2018;33 (8):791-801. doi: 10.14670/HH-11-973. PubMed PMID:29441509 .

Search PubMed

2017
  1. Lehtinen, B, Raita, A, Kesseli, J, Annala, M, Nordfors, K, Yli-Harja, O et al.. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. 2017;17 (1):310. doi: 10.1186/s12885-017-3274-9. PubMed PMID:28468611 PubMed Central PMC5415775.
  2. Granberg, KJ, Annala, M, Lehtinen, B, Kesseli, J, Haapasalo, J, Ruusuvuori, P et al.. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. 2017;19 (9):1206-1216. doi: 10.1093/neuonc/nox028. PubMed PMID:28379477 PubMed Central PMC5570261.

Search PubMed

Murtola Group

Pharmacoepidemiology and Chemoprevention

 

2020
  1. Santala, EEE, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Angiotensin Receptor Blockers Associated with Improved Breast Cancer Survival-A Nationwide Cohort Study from Finland. 2020; :. doi: 10.1158/1055-9965.EPI-20-0711. PubMed PMID:32917663 .
  2. Raittinen, P, Niemistö, K, Pennanen, E, Syvälä, H, Auriola, S, Riikonen, J et al.. Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer. 2020;10 (1):12016. doi: 10.1038/s41598-020-68868-5. PubMed PMID:32694638 PubMed Central PMC7374714.
  3. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
  4. Omar, MI, Roobol, MJ, Ribal, MJ, Abbott, T, Agapow, PM, Araujo, S et al.. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research. 2020;17 (8):482. doi: 10.1038/s41585-020-0355-3. PubMed PMID:32587405 .
  5. Omar, MI, Roobol, MJ, Ribal, MJ, Abbott, T, Agapow, PM, Araujo, S et al.. Introducing PIONEER: a project to harness big data in prostate cancer research. 2020;17 (6):351-362. doi: 10.1038/s41585-020-0324-x. PubMed PMID:32461687 .
  6. Riikonen, J, Pakarainen, T, Siltari, A, Pienimäki, JP, Koskimäki, J, Murtola, TJ et al.. Urine colour as an indicator for anastomotic leakage after robot-assisted radical prostatectomy. 2020;54 (3):201-207. doi: 10.1080/21681805.2020.1750474. PubMed PMID:32308088 .
  7. Kinnunen, PT, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study. 2020;29 (1):208-215. doi: 10.1158/1055-9965.EPI-19-0147. PubMed PMID:31653681 .
  8. Santala, EEE, Rannikko, A, Murtola, TJ. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. 2020;146 (4):1175. doi: 10.1002/ijc.32745. PubMed PMID:31633796 .

Search PubMed

2019
  1. Pylväläinen, J, Talala, K, Murtola, T, Taari, K, Raitanen, J, Tammela, TL et al.. Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time. 2019;11 :923-932. doi: 10.2147/CLEP.S218697. PubMed PMID:31695505 PubMed Central PMC6805117.
  2. Kinnunen, PT, Murto, MO, Artama, M, Pukkala, E, Visvanathan, K, Murtola, TJ et al.. Anticoagulants and Breast Cancer Survival: A Nationwide Cohort Study. 2020;29 (1):208-215. doi: 10.1158/1055-9965.EPI-19-0147. PubMed PMID:31653681 .
  3. Santala, EEE, Rannikko, A, Murtola, TJ. Reply to: Calcium channel blockers therapy and the risk of prostate cancer death. 2020;146 (4):1175. doi: 10.1002/ijc.32745. PubMed PMID:31633796 .
  4. Siltari, A, Riikonen, J, Fode, M, Murtola, TJ. Effects of Preoperative Atorvastatin Treatment On Erectile Function After Radical Prostatectomy: Results From a Subgroup of ESTO1, a Randomized, Double-Blind, Placebo-Controlled Study. 2019;16 (10):1597-1605. doi: 10.1016/j.jsxm.2019.07.001. PubMed PMID:31405764 .
  5. Santala, EEE, Kotsar, A, Veitonmäki, T, Tammela, TLJ, Murtola, TJ. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. 2019;53 (4):185-192. doi: 10.1080/21681805.2019.1634147. PubMed PMID:31250699 .
  6. Joentausta, RM, Murtola, TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. Prostate. 2019;79:583-591. 2019;79 (12):1420-1421. doi: 10.1002/pros.23870. PubMed PMID:31233216 .
  7. Knuuttila, E, Riikonen, J, Syvälä, H, Auriola, S, Murtola, TJ. Access and concentrations of atorvastatin in the prostate in men with prostate cancer. 2019;79 (12):1412-1419. doi: 10.1002/pros.23863. PubMed PMID:31231865 .
  8. Murtola, TJ, Veitonmäki, T. Aspirin and Prostate Cancer Mortality: The Role of Tumor Grading Misclassification?. 2019;170 (7):499-500. doi: 10.7326/M19-0525. PubMed PMID:30831583 .
  9. Murtola, TJ, Syvälä, H, Riikonen, J. Reply to Jae Heon Kim and Benjamin I. Chung’s Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701. 2019;75 (6):e166-e167. doi: 10.1016/j.eururo.2019.01.044. PubMed PMID:30738709 .
  10. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
  11. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
  12. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  13. Joentausta, RM, Rannikko, A, Murtola, TJ. Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort. 2019;79 (6):583-591. doi: 10.1002/pros.23768. PubMed PMID:30652328 .
  14. Østergren, PB, Murtola, TJ, Fode, M. Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2. 2019;75 (6):938-939. doi: 10.1016/j.eururo.2018.12.016. PubMed PMID:30573315 .
  15. Häkkinen, MR, Murtola, T, Voutilainen, R, Poutanen, M, Linnanen, T, Koskivuori, J et al.. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. 2019;164 :642-652. doi: 10.1016/j.jpba.2018.11.035. PubMed PMID:30472582 .
  16. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  17. Santala, EE, Rannikko, A, Murtola, TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. 2019;144 (3):440-447. doi: 10.1002/ijc.31802. PubMed PMID:30110124 .
  18. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.

Search PubMed

2018
  1. Salminen, AP, Koskinen, I, Perez, IM, Hurme, S, Murtola, TJ, Vaarala, MH et al.. Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. 2018;1 (6):525-530. doi: 10.1016/j.euo.2018.06.014. PubMed PMID:31158099 .
  2. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. ;52 (5-6):321-327. doi: 10.1080/21681805.2018.1559882. PubMed PMID:30698056 .
  3. Østergren, PB, Murtola, TJ, Fode, M. Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2. 2019;75 (6):938-939. doi: 10.1016/j.eururo.2018.12.016. PubMed PMID:30573315 .
  4. Häkkinen, MR, Murtola, T, Voutilainen, R, Poutanen, M, Linnanen, T, Koskivuori, J et al.. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. 2019;164 :642-652. doi: 10.1016/j.jpba.2018.11.035. PubMed PMID:30472582 .
  5. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
  6. Rantaniemi, L, Tammela, TLJ, Kujala, P, Murtola, TJ. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. 2018;52 (4):269-276. doi: 10.1080/21681805.2018.1492967. PubMed PMID:30362865 .
  7. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  8. Santala, EE, Rannikko, A, Murtola, TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. 2019;144 (3):440-447. doi: 10.1002/ijc.31802. PubMed PMID:30110124 .
  9. Murtola, TJ, Syvälä, H, Tolonen, T, Helminen, M, Riikonen, J, Koskimäki, J et al.. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. 2018;74 (6):697-701. doi: 10.1016/j.eururo.2018.06.037. PubMed PMID:30031572 .
  10. Kaapu, KJ, Rantaniemi, L, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. 2018;8 (1):10308. doi: 10.1038/s41598-018-28541-4. PubMed PMID:29985440 PubMed Central PMC6037774.
  11. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
  12. Mäkelä, VJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. 2018;200 (4):743-748. doi: 10.1016/j.juro.2018.04.082. PubMed PMID:29730200 .
  13. Murtola, TJ, Vihervuori, VJ, Lahtela, J, Talala, K, Taari, K, Tammela, TL et al.. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2018;118 (9):1248-1254. doi: 10.1038/s41416-018-0055-4. PubMed PMID:29563633 PubMed Central PMC5943324.
  14. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  15. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .

Search PubMed

2017
  1. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  2. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  3. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;17 (1):585. doi: 10.1186/s12885-017-3579-8. PubMed PMID:28851310 PubMed Central PMC5575900.
  4. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .
  5. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  6. Eskelinen, TJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Components of metabolic syndrome and prognosis of renal cell cancer. 2017;51 (6):435-441. doi: 10.1080/21681805.2017.1352616. PubMed PMID:28743221 .
  7. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. 2017;77 (9):1029-1035. doi: 10.1002/pros.23359. PubMed PMID:28480542 .
  8. Murtola, TJ, Virkku, A, Talala, K, Stenman, UH, Taari, K, Tammela, TLJ et al.. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. 2017;198 (2):305-309. doi: 10.1016/j.juro.2017.02.069. PubMed PMID:28216328 .
  9. Wettstein, MS, Saba, K, Umbehr, MH, Murtola, TJ, Fankhauser, CD, Adank, JP et al.. Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. 2017;77 (5):549-556. doi: 10.1002/pros.23296. PubMed PMID:28093792 .
  10. Haring, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;51 (1):5-12. doi: 10.1080/21681805.2016.1271353. PubMed PMID:28084175 .

Search PubMed

2016
  1. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  2. Syvälä, H, Pennanen, P, Bläuer, M, Tammela, TL, Murtola, TJ. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. 2016;481 (1-2):46-50. doi: 10.1016/j.bbrc.2016.11.021. PubMed PMID:27833018 .
  3. Kinnunen, PT, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;50 (6):413-419. doi: 10.1080/21681805.2016.1228085. PubMed PMID:27628763 .
  4. Kaapu, KJ, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;115 (11):1289-1295. doi: 10.1038/bjc.2016.328. PubMed PMID:27755533 PubMed Central PMC5129833.
  5. Pennanen, P, Syvälä, H, Bläuer, M, Savinainen, K, Ylikomi, T, Tammela, TLJ et al.. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines. 2016;788 :160-167. doi: 10.1016/j.ejphar.2016.06.036. PubMed PMID:27341997 .
  6. Veitonmäki, T, Murtola, TJ, Talala, K, Taari, K, Tammela, T, Auvinen, A et al.. Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. 2016;11 (4):e0153413. doi: 10.1371/journal.pone.0153413. PubMed PMID:27100876 PubMed Central PMC4839624.
  7. Gusev, A, Shi, H, Kichaev, G, Pomerantz, M, Li, F, Long, HW et al.. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. 2016;7 :10979. doi: 10.1038/ncomms10979. PubMed PMID:27052111 PubMed Central PMC4829663.
  8. Salminen, JK, Tammela, TL, Auvinen, A, Murtola, TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. 2016;27 (5):637-45. doi: 10.1007/s10552-016-0737-2. PubMed PMID:27038166 .
  9. Sarre, S, Määttänen, L, Tammela, TL, Auvinen, A, Murtola, TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. 2016;50 (4):267-73. doi: 10.3109/21681805.2016.1145734. PubMed PMID:26927237 .
  10. Murtola, TJ, Karppa, EK, Taari, K, Talala, K, Tammela, TL, Auvinen, A et al.. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. 2016;138 (12):2820-8. doi: 10.1002/ijc.30017. PubMed PMID:26804670 .
  11. Murtola, TJ, Gurel, B, Umbehr, M, Lucia, MS, Thompson, IM Jr, Goodman, PJ et al.. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. 2016;25 (3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. PubMed PMID:26715424 PubMed Central PMC4779655.
  12. Keskiväli, T, Kujala, P, Visakorpi, T, Tammela, TL, Murtola, TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. 2016;76 (5):469-78. doi: 10.1002/pros.23138. PubMed PMID:26689439 .

Search PubMed

2015
  1. Murtola, TJ, Gurel, B, Umbehr, M, Lucia, MS, Thompson, IM Jr, Goodman, PJ et al.. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. 2016;25 (3):463-9. doi: 10.1158/1055-9965.EPI-15-0987. PubMed PMID:26715424 PubMed Central PMC4779655.
  2. Keskiväli, T, Kujala, P, Visakorpi, T, Tammela, TL, Murtola, TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. 2016;76 (5):469-78. doi: 10.1002/pros.23138. PubMed PMID:26689439 .
  3. Wennberg, CL, Murtola, T, Páll, S, Abraham, MJ, Hess, B, Lindahl, E et al.. Direct-Space Corrections Enable Fast and Accurate Lorentz-Berthelot Combination Rule Lennard-Jones Lattice Summation. 2015;11 (12):5737-46. doi: 10.1021/acs.jctc.5b00726. PubMed PMID:26587968 .
  4. Davies, NM, Gaunt, TR, Lewis, SJ, Holly, J, Donovan, JL, Hamdy, FC et al.. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. 2015;26 (11):1603-16. doi: 10.1007/s10552-015-0654-9. PubMed PMID:26387087 PubMed Central PMC4596899.
  5. Szulkin, R, Whitington, T, Eklund, M, Aly, M, Eeles, RA, Easton, D et al.. Prediction of individual genetic risk to prostate cancer using a polygenic score. 2015;75 (13):1467-74. doi: 10.1002/pros.23037. PubMed PMID:26177737 .
  6. Veitonmäki, T, Murtola, TJ, Määttänen, L, Taari, K, Stenman, UH, Tammela, TL et al.. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. 2015;75 (13):1394-402. doi: 10.1002/pros.23020. PubMed PMID:26073992 .
  7. Amin Al Olama, A, Dadaev, T, Hazelett, DJ, Li, Q, Leongamornlert, D, Saunders, EJ et al.. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. 2015;24 (19):5589-602. doi: 10.1093/hmg/ddv203. PubMed PMID:26025378 PubMed Central PMC4572072.
  8. Murtola, TJ, Wahlfors, T, Haring, A, Taari, K, Stenman, UH, Tammela, TL et al.. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. 2015;68 (6):1089-97. doi: 10.1016/j.eururo.2015.03.026. PubMed PMID:25819720 .
  9. Stegeman, S, Amankwah, E, Klein, K, O’Mara, TA, Kim, D, Lin, HY et al.. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. 2015;5 (4):368-79. doi: 10.1158/2159-8290.CD-14-1057. PubMed PMID:25691096 PubMed Central PMC4390388.
  10. Kaapu, KJ, Ahti, J, Tammela, TL, Auvinen, A, Murtola, TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. 2015;137 (5):1187-95. doi: 10.1002/ijc.29470. PubMed PMID:25656312 .

Search PubMed

Nykter Group

Computational Biology

https://scholar.google.com/citations?user=2GZr1tgAAAAJ&hl=en

Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J, Tammela TLJ, Kivinummi K, Latonen L, Nykter M, Visakorpi T. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 2020 Jul;39(30):5241-5251. doi: 10.1038/s41388-020-1365-6. Epub 2020 Jun 17. PMID: 32555329.

Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020 Sep 14;38(3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. Epub 2020 Jul 9. Erratum in: Cancer Cell. 2020 Sep 14;38(3):424-428. PMID: 32649887.

Vandekerkhove G, Struss WJ, Annala M, Kallio HML, Khalaf D, Warner EW, Herberts C, Ritch E, Beja K, Loktionova Y, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10. PMID: 30638634.

Taavitsainen S, Annala M, Ledet E, Beja K, Miller PJ, Moses M, Nykter M, Chi KN, Sartor O, Wyatt AW. Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer. JCO Precis Oncol. 2019 Jun 12;3:PO.19.00014. doi: 10.1200/PO.19.00014. PMID: 32914020; PMCID: PMC7446428.

Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg KJ, Lohi O, Nykter M, Heinäniemi M. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019 May 15;79(10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. Epub 2019 Apr 2. PMID: 30940663.

Mehtonen J, Pölönen P, Häyrynen S, Dufva O, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. Data-driven characterization of molecular phenotypes across heterogeneous sample collections. Nucleic Acids Res. 2019 Jul 26;47(13):e76. doi: 10.1093/nar/gkz281. PMID: 31329928; PMCID: PMC6648337.

Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, Kivinummi KK, Tammela TTL, Beuerman RW, Uusitalo H, Nykter M, Visakorpi T. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018 Mar 21;9(1):1176. doi: 10.1038/s41467-018-03573-6. PMID: 29563510; PMCID: PMC5862881.

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24. PMID: 29367197.

Annala M, Taavitsainen S, Vandekerkhove G, Bacon JVW, Beja K, Chi KN, Nykter M, Wyatt AW. Frequent mutation of the FOXA1 untranslated region in prostate cancer. Commun Biol. 2018 Aug 24;1:122. doi: 10.1038/s42003-018-0128-1. PMID: 30272002; PMCID: PMC6123809.

Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; Cancer Genome Atlas Research Network, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018 Apr 3;23(1):227-238.e3. doi: 10.1016/j.celrep.2018.03.050. PMID: 29617662; PMCID: PMC5916809.

Ruusuvuori Group

Bioimage Informatics

Valkonen, M., Högnäs, G., Bova, G.S., Ruusuvuori, P. Generalized fixation invariant nuclei detection through domain adaptation based deep learning, IEEE Journal of Biomedical and Health Informatics, 12 pages, in press, 2020

Ström, P., Kartasalo, K., Olsson, H., Solorzano, L., Delahunt, B., Berney, D. M., …Ruusuvuori, P. … & Eklund, M. (2020). Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. The Lancet Oncology, 21(2), 222-232.

Valkonen, J. Isola, O. Ylinen, V. Muhonen, A. Saxlin, T. Tolonen, M. Nykter, P. Ruusuvuori. (2020). Cytokeratin-supervised deep learning for automatic recognition of epithelial cells in breast cancers stained for ER, PR, and Ki-67. IEEE Transactions on Medical Imaging, 39(2), 534-542.

Liimatainen, L. Kananen, L. Latonen, P. Ruusuvuori. Iterative unsupervised domain adaptation for generalized cell detection from brightfield z-stacks. BMC Bioinformatics, 20 (1), 80, 2019. 10.1186/s12859-019-2605-z

Kartasalo, L. Latonen.M. Vihinen, T. Visakorpi, M. Nykter, P. Ruusuvuori. Comparative analysis of tissue reconstruction algorithms for 3D histology. Bioinformatics, bty210, https://doi.org/10.1093/bioinformatics/bty210, 2018

Ehteshami Bejnordi, M. Veta, PJ van Diest, B. van Ginneken, N. Karssemeijer, G. Litjens, JAWM van der Laak, The CAMELYON16 Consortium. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA 318 (22), 2199-2210

Valkonen, K. Kartasalo, K. Liimatainen, M. Nykter, L. Latonen, P. Ruusuvuori, Metastasis detection from whole slide images using local features and random forests. Cytometry A, 2017. doi:10.1002/cyto.a.23089

Valkonen, P. Ruusuvuori, K. Kartasalo, M. Nykter, T. Visakorpi, L. Latonen, Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models. Scientific Reports, 2017. dx.doi.org/10.1038/srep44831

Ruusuvuori, L. Paavolainen, K. Rutanen, A. Mäki, H. Huttunen, V. Marjomäki. (2014) Quantitative Analysis of Dynamic Association in Live Biological Fluorescent Samples. PLoS ONE 9(4): e94245. doi:10.1371/journal.pone.0094245

Ruusuvuori, J. Lin, AC. Scott, Z. Tan, S. Sorsa, A. Kallio, M. Nykter, O. Yli-Harja, I. Shmulevich, AM. Dudley, Quantitative analysis of colony morphology in yeast, BioTechniques, Vol. 56, No. 1, Jan 2014, pp. 18–27.

Schleutker Group

Genetic Predisposition to Prostate Cancer

 

2020
  1. Schaid, DJ, McDonnell, SK, FitzGerald, LM, DeRycke, L, Fogarty, Z, Giles, GG et al.. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. 2020; :. doi: 10.1016/j.eururo.2020.07.038. PubMed PMID:32800727 .
  2. Wu, L, Yang, Y, Guo, X, Shu, XO, Cai, Q, Shu, X et al.. An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. 2020;11 (1):3905. doi: 10.1038/s41467-020-17673-9. PubMed PMID:32764609 PubMed Central PMC7413371.
  3. Rathinakannan, VS, Schukov, HP, Heron, S, Schleutker, J, Sipeky, C. ShAn: An easy-to-use tool for interactive and integrated variant annotation. 2020;15 (7):e0235669. doi: 10.1371/journal.pone.0235669. PubMed PMID:32634151 PubMed Central PMC7340278.
  4. Huynh-Le, MP, Fan, CC, Karunamuni, R, Walsh, EI, Turner, EL, Lane, JA et al.. A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. 2020;29 (9):1731-1738. doi: 10.1158/1055-9965.EPI-19-1527. PubMed PMID:32581112 PubMed Central PMC7483627.
  5. Karunamuni, RA, Huynh-Le, MP, Fan, CC, Eeles, RA, Easton, DF, Kote-Jarai, Z et al.. The effect of sample size on polygenic hazard models for prostate cancer. 2020;28 (10):1467-1475. doi: 10.1038/s41431-020-0664-2. PubMed PMID:32514134 .
  6. Hollis, B, Day, FR, Busch, AS, Thompson, DJ, Soares, ALG, Timmers, PRHJ et al.. Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. 2020;11 (1):1536. doi: 10.1038/s41467-020-14451-5. PubMed PMID:32210231 PubMed Central PMC7093467.
  7. Rantapero, T, Wahlfors, T, Kähler, A, Hultman, C, Lindberg, J, Tammela, TL et al.. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. 2020;11 (3):. doi: 10.3390/genes11030314. PubMed PMID:32183364 PubMed Central PMC7140841.
  8. Kaikkonen, E, Takala, A, Pursiheimo, JP, Wahlström, G, Schleutker, J. The interactome of the prostate-specific protein Anoctamin 7. 2020;28 (1):91-100. doi: 10.3233/CBM-190993. PubMed PMID:32176628 PubMed Central PMC7306890.

Search PubMed

2019
  1. Kaikkonen, E, Ettala, O, Nikulainen, I, Taimen, P, Lehtinen, I, Boström, PJ et al.. ANO7 rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. 2019;39 (10):5353-5359. doi: 10.21873/anticanres.13728. PubMed PMID:31570429 .
  2. Tabassum, R, Rämö, JT, Ripatti, P, Koskela, JT, Kurki, M, Karjalainen, J et al.. Genetic architecture of human plasma lipidome and its link to cardiovascular disease. 2019;10 (1):4329. doi: 10.1038/s41467-019-11954-8. PubMed PMID:31551469 PubMed Central PMC6760179.
  3. Jiang, X, Finucane, HK, Schumacher, FR, Schmit, SL, Tyrer, JP, Han, Y et al.. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. 2019;10 (1):4386. doi: 10.1038/s41467-019-12095-8. PubMed PMID:31548585 PubMed Central PMC6757065.
  4. Law, PJ, Timofeeva, M, Fernandez-Rozadilla, C, Broderick, P, Studd, J, Fernandez-Tajes, J et al.. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 2019;10 (1):2154. doi: 10.1038/s41467-019-09775-w. PubMed PMID:31089142 PubMed Central PMC6517433.
  5. Kuuluvainen, L, Kaivola, K, Mönkäre, S, Laaksovirta, H, Jokela, M, Udd, B et al.. Oligogenic basis of sporadic ALS: The example of SOD1 p.Ala90Val mutation. 2019;5 (3):e335. doi: 10.1212/NXG.0000000000000335. PubMed PMID:31086828 PubMed Central PMC6481226.
  6. Nurmi, A, Muranen, TA, Pelttari, LM, Kiiski, JI, Heikkinen, T, Lehto, S et al.. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. 2019;145 (10):2692-2700. doi: 10.1002/ijc.32309. PubMed PMID:30927251 PubMed Central PMC6767104.
  7. Jiang, X, Finucane, HK, Schumacher, FR, Schmit, SL, Tyrer, JP, Han, Y et al.. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019;10 (1):431. doi: 10.1038/s41467-018-08054-4. PubMed PMID:30683880 PubMed Central PMC6347624.
  8. Vijayakrishnan, J, Studd, J, Broderick, P, Kinnersley, B, Holroyd, A, Law, PJ et al.. Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. 2019;10 (1):419. doi: 10.1038/s41467-018-08106-9. PubMed PMID:30664635 PubMed Central PMC6341085.
  9. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  10. Went, M, Sud, A, Försti, A, Halvarsson, BM, Weinhold, N, Kimber, S et al.. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 2019;10 (1):213. doi: 10.1038/s41467-018-08107-8. PubMed PMID:30631080 PubMed Central PMC6328616.
  11. Schumacher, FR, Olama, AAA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2019;51 (2):363. doi: 10.1038/s41588-018-0330-6. PubMed PMID:30622367 .
  12. Sud, A, Thomsen, H, Law, PJ, Försti, A, da Silva Filho, MI, Holroyd, A et al.. Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. 2019;10 (1):157. doi: 10.1038/s41467-018-08105-w. PubMed PMID:30622283 PubMed Central PMC6325156.
  13. Mancuso, N, Gayther, S, Gusev, A, Zheng, W, Penney, KL, PRACTICAL consortium et al.. Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. 2019;10 (1):171. doi: 10.1038/s41467-018-08108-7. PubMed PMID:30622272 PubMed Central PMC6325152.
  14. Li-Sheng Chen, S, Ching-Yuan Fann, J, Sipeky, C, Yang, TK, Yueh-Hsia Chiu, S, Ming-Fang Yen, A et al.. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. 2019;201 (3):486-495. doi: 10.1016/j.juro.2018.10.015. PubMed PMID:30366021 .
  15. Adams, CD, Richmond, R, Ferreira, DLS, Spiller, W, Tan, V, Zheng, J et al.. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. 2019;28 (1):208-216. doi: 10.1158/1055-9965.EPI-18-0079. PubMed PMID:30352818 PubMed Central PMC6746173.

Search PubMed

2018
  1. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
  2. Adams, CD, Richmond, R, Ferreira, DLS, Spiller, W, Tan, V, Zheng, J et al.. Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. 2019;28 (1):208-216. doi: 10.1158/1055-9965.EPI-18-0079. PubMed PMID:30352818 PubMed Central PMC6746173.
  3. Mancuso, N, Gayther, S, Gusev, A, Zheng, W, Penney, KL, Kote-Jarai, Z et al.. Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. 2018;9 (1):4079. doi: 10.1038/s41467-018-06302-1. PubMed PMID:30287866 PubMed Central PMC6172280.
  4. Went, M, Sud, A, Försti, A, Halvarsson, BM, Weinhold, N, Kimber, S et al.. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 2018;9 (1):3707. doi: 10.1038/s41467-018-04989-w. PubMed PMID:30213928 PubMed Central PMC6137048.
  5. Sipeky, C, Gao, P, Zhang, Q, Wang, L, Ettala, O, Talala, KM et al.. Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer. 2018;24 (24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. PubMed PMID:30181389 PubMed Central PMC6719560.
  6. Kaikkonen, E, Rantapero, T, Zhang, Q, Taimen, P, Laitinen, V, Kallajoki, M et al.. ANO7 is associated with aggressive prostate cancer. 2018;143 (10):2479-2487. doi: 10.1002/ijc.31746. PubMed PMID:30157291 PubMed Central PMC6589920.
  7. Gao, P, Xia, JH, Sipeky, C, Dong, XM, Zhang, Q, Yang, Y et al.. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. 2018;174 (3):576-589.e18. doi: 10.1016/j.cell.2018.06.003. PubMed PMID:30033361 PubMed Central PMC6091222.
  8. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
  9. Schumacher, FR, Al Olama, AA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2018;50 (7):928-936. doi: 10.1038/s41588-018-0142-8. PubMed PMID:29892016 PubMed Central PMC6568012.
  10. Lin, HY, Huang, PY, Chen, DT, Tung, HY, Sellers, TA, Pow-Sang, JM et al.. AA9int: SNP interaction pattern search using non-hierarchical additive model set. 2018;34 (24):4141-4150. doi: 10.1093/bioinformatics/bty461. PubMed PMID:29878078 PubMed Central PMC6289141.
  11. Vijayakrishnan, J, Studd, J, Broderick, P, Kinnersley, B, Holroyd, A, Law, PJ et al.. Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. 2018;9 (1):1340. doi: 10.1038/s41467-018-03178-z. PubMed PMID:29632299 PubMed Central PMC5890276.
  12. Saunders, EJ, Dadaev, T, Leongamornlert, DA, Al Olama, AA, Benlloch, S, Giles, GG et al.. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. 2018;118 (6):e9. doi: 10.1038/bjc.2017.468. PubMed PMID:29438362 PubMed Central PMC5877430.
  13. Seibert, TM, Fan, CC, Wang, Y, Zuber, V, Karunamuni, R, Parsons, JK et al.. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 2018;360 :j5757. doi: 10.1136/bmj.j5757. PubMed PMID:29321194 PubMed Central PMC5759091.

Search PubMed

2017
  1. Sud, A, Thomsen, H, Law, PJ, Försti, A, Filho, MIDS, Holroyd, A et al.. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. 2017;8 (1):1892. doi: 10.1038/s41467-017-00320-1. PubMed PMID:29196614 PubMed Central PMC5711884.
  2. Dimitrakopoulou, VI, Tsilidis, KK, Haycock, PC, Dimou, NL, Al-Dabhani, K, Martin, RM et al.. Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 2017;359 :j4761. doi: 10.1136/bmj.j4761. PubMed PMID:29089348 PubMed Central PMC5666592.
  3. Lophatananon, A, Stewart-Brown, S, Kote-Jarai, Z, Olama, AAA, Garcia, SB, Neal, DE et al.. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. 2017;117 (5):734-743. doi: 10.1038/bjc.2017.231. PubMed PMID:28765617 PubMed Central PMC5572182.
  4. Määttä, KM, Nurminen, R, Kankuri-Tammilehto, M, Kallioniemi, A, Laasanen, SL, Schleutker, J et al.. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families. 2017;17 (1):496. doi: 10.1186/s12885-017-3488-x. PubMed PMID:28738860 PubMed Central PMC5525221.
  5. Kiiski, JI, Tervasmäki, A, Pelttari, LM, Khan, S, Mantere, T, Pylkäs, K et al.. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. 2017;166 (1):217-226. doi: 10.1007/s10549-017-4388-0. PubMed PMID:28702895 PubMed Central PMC5645429.
  6. Chen, Y, Zhang, Q, Wang, Q, Li, J, Sipeky, C, Xia, J et al.. Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression. 2017;7 (1):4538. doi: 10.1038/s41598-017-04731-4. PubMed PMID:28674394 PubMed Central PMC5495790.
  7. Na, R, Helfand, BT, Chen, H, Conran, CA, Crawford, SE, Hayward, SW et al.. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). 2017;77 (11):1213-1220. doi: 10.1002/pros.23380. PubMed PMID:28656603 PubMed Central PMC5565164.
  8. Mantere, T, Tervasmäki, A, Nurmi, A, Rapakko, K, Kauppila, S, Tang, J et al.. Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. 2017;7 (1):681. doi: 10.1038/s41598-017-00766-9. PubMed PMID:28386063 PubMed Central PMC5429682.
  9. Zuber, V, Bettella, F, Witoelar, A, PRACTICAL Consortium, CRUK GWAS, BCAC Consortium et al.. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. 2017;18 (1):270. doi: 10.1186/s12864-017-3620-y. PubMed PMID:28359301 PubMed Central PMC5374680.
  10. Larson, NB, McDonnell, S, Cannon Albright, L, Teerlink, C, Stanford, J, Ostrander, EA et al.. gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. 2017;41 (4):297-308. doi: 10.1002/gepi.22036. PubMed PMID:28211093 PubMed Central PMC5397327.
  11. Lin, HY, Chen, DT, Huang, PY, Liu, YH, Ochoa, A, Zabaleta, J et al.. SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. 2017;33 (6):822-833. doi: 10.1093/bioinformatics/btw762. PubMed PMID:28039167 PubMed Central PMC5860469.
  12. Taylor, AE, Martin, RM, Geybels, MS, Stanford, JL, Shui, I, Eeles, R et al.. Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. 2017;140 (2):322-328. doi: 10.1002/ijc.30462. PubMed PMID:27741566 PubMed Central PMC5132137.
  13. Brunner, C, Davies, NM, Martin, RM, Eeles, R, Easton, D, Kote-Jarai, Z et al.. Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. 2017;140 (1):75-85. doi: 10.1002/ijc.30436. PubMed PMID:27643404 PubMed Central PMC5111609.

Search PubMed

2016
  1. Luedeke, M, Rinckleb, AE, FitzGerald, LM, Geybels, MS, Schleutker, J, Eeles, RA et al.. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. 2016;25 (24):5490-5499. doi: 10.1093/hmg/ddw349. PubMed PMID:27798103 PubMed Central PMC5418832.
  2. Määttä, K, Rantapero, T, Lindström, A, Nykter, M, Kankuri-Tammilehto, M, Laasanen, SL et al.. Whole-exome sequencing of Finnish hereditary breast cancer families. 2016;25 (1):85-93. doi: 10.1038/ejhg.2016.141. PubMed PMID:27782108 PubMed Central PMC5159774.
  3. Taylor, AE, Martin, RM, Geybels, MS, Stanford, JL, Shui, I, Eeles, R et al.. Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. 2017;140 (2):322-328. doi: 10.1002/ijc.30462. PubMed PMID:27741566 PubMed Central PMC5132137.
  4. Ioannidis, NM, Rothstein, JH, Pejaver, V, Middha, S, McDonnell, SK, Baheti, S et al.. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. 2016;99 (4):877-885. doi: 10.1016/j.ajhg.2016.08.016. PubMed PMID:27666373 PubMed Central PMC5065685.
  5. Brunner, C, Davies, NM, Martin, RM, Eeles, R, Easton, D, Kote-Jarai, Z et al.. Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. 2017;140 (1):75-85. doi: 10.1002/ijc.30436. PubMed PMID:27643404 PubMed Central PMC5111609.
  6. Southey, MC, Goldgar, DE, Winqvist, R, Pylkäs, K, Couch, F, Tischkowitz, M et al.. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. 2016;53 (12):800-811. doi: 10.1136/jmedgenet-2016-103839. PubMed PMID:27595995 PubMed Central PMC5200636.
  7. Khankari, NK, Murff, HJ, Zeng, C, Wen, W, Eeles, RA, Easton, DF et al.. Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. 2016;115 (5):624-31. doi: 10.1038/bjc.2016.228. PubMed PMID:27490808 PubMed Central PMC4997551.
  8. Kar, SP, Beesley, J, Amin Al Olama, A, Michailidou, K, Tyrer, J, Kote-Jarai, Z et al.. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 2016;6 (9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. PubMed PMID:27432226 PubMed Central PMC5010513.
  9. Larson, NB, McDonnell, S, Albright, LC, Teerlink, C, Stanford, J, Ostrander, EA et al.. Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. 2016;40 (6):461-9. doi: 10.1002/gepi.21983. PubMed PMID:27312771 PubMed Central PMC5063501.
  10. Teerlink, CC, Leongamornlert, D, Dadaev, T, Thomas, A, Farnham, J, Stephenson, RA et al.. Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. 2016;135 (8):923-38. doi: 10.1007/s00439-016-1690-6. PubMed PMID:27262462 PubMed Central PMC5020907.
  11. Bonilla, C, Lewis, SJ, Rowlands, MA, Gaunt, TR, Davey Smith, G, Gunnell, D et al.. Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. 2016;139 (7):1520-33. doi: 10.1002/ijc.30206. PubMed PMID:27225428 PubMed Central PMC4957617.
  12. Pelttari, LM, Khan, S, Vuorela, M, Kiiski, JI, Vilske, S, Nevanlinna, V et al.. RAD51B in Familial Breast Cancer. 2016;11 (5):e0153788. doi: 10.1371/journal.pone.0153788. PubMed PMID:27149063 PubMed Central PMC4858276.
  13. Nurminen, R, Rantapero, T, Wong, SC, Fischer, D, Lehtonen, R, Tammela, TL et al.. Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. 2016;55 (8):661-73. doi: 10.1002/gcc.22368. PubMed PMID:27113481 .
  14. Gusev, A, Shi, H, Kichaev, G, Pomerantz, M, Li, F, Long, HW et al.. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. 2016;7 :10979. doi: 10.1038/ncomms10979. PubMed PMID:27052111 PubMed Central PMC4829663.
  15. Bonilla, C, Lewis, SJ, Martin, RM, Donovan, JL, Hamdy, FC, Neal, DE et al.. Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. 2016;14 :66. doi: 10.1186/s12916-016-0602-x. PubMed PMID:27044414 PubMed Central PMC4820939.
  16. Bull, CJ, Bonilla, C, Holly, JM, Perks, CM, Davies, N, Haycock, P et al.. Blood lipids and prostate cancer: a Mendelian randomization analysis. 2016;5 (6):1125-36. doi: 10.1002/cam4.695. PubMed PMID:26992435 PubMed Central PMC4924371.
  17. Saunders, EJ, Dadaev, T, Leongamornlert, DA, Al Olama, AA, Benlloch, S, Giles, GG et al.. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. 2016;114 (8):945-52. doi: 10.1038/bjc.2016.50. PubMed PMID:26964030 PubMed Central PMC5379914.
  18. Sjöblom, L, Saramäki, O, Annala, M, Leinonen, K, Nättinen, J, Tolonen, T et al.. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. 2016;11 (3):e0150241. doi: 10.1371/journal.pone.0150241. PubMed PMID:26939004 PubMed Central PMC4777373.
  19. Laitinen, VH, Akinrinade, O, Rantapero, T, Tammela, TL, Wahlfors, T, Schleutker, J et al.. Germline copy number variation analysis in Finnish families with hereditary prostate cancer. 2016;76 (3):316-24. doi: 10.1002/pros.23123. PubMed PMID:26552734 .

Search PubMed

2015
  1. Laitinen, VH, Akinrinade, O, Rantapero, T, Tammela, TL, Wahlfors, T, Schleutker, J et al.. Germline copy number variation analysis in Finnish families with hereditary prostate cancer. 2016;76 (3):316-24. doi: 10.1002/pros.23123. PubMed PMID:26552734 .
  2. Davies, NM, Gaunt, TR, Lewis, SJ, Holly, J, Donovan, JL, Hamdy, FC et al.. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. 2015;26 (11):1603-16. doi: 10.1007/s10552-015-0654-9. PubMed PMID:26387087 PubMed Central PMC4596899.
  3. Szulkin, R, Karlsson, R, Whitington, T, Aly, M, Gronberg, H, Eeles, RA et al.. Genome-wide association study of prostate cancer-specific survival. 2015;24 (11):1796-800. doi: 10.1158/1055-9965.EPI-15-0543. PubMed PMID:26307654 PubMed Central PMC5674990.
  4. Pashayan, N, Pharoah, PD, Schleutker, J, Talala, K, Tammela, TLj, Määttänen, L et al.. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. 2015;113 (7):1086-93. doi: 10.1038/bjc.2015.289. PubMed PMID:26291059 PubMed Central PMC4651137.
  5. Szulkin, R, Whitington, T, Eklund, M, Aly, M, Eeles, RA, Easton, D et al.. Prediction of individual genetic risk to prostate cancer using a polygenic score. 2015;75 (13):1467-74. doi: 10.1002/pros.23037. PubMed PMID:26177737 .
  6. Amin Al Olama, A, Dadaev, T, Hazelett, DJ, Li, Q, Leongamornlert, D, Saunders, EJ et al.. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. 2015;24 (19):5589-602. doi: 10.1093/hmg/ddv203. PubMed PMID:26025378 PubMed Central PMC4572072.
  7. Fischer, D, Wahlfors, T, Mattila, H, Oja, H, Tammela, TL, Schleutker, J et al.. MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families. 2015;10 (5):e0127427. doi: 10.1371/journal.pone.0127427. PubMed PMID:26020509 PubMed Central PMC4447459.
  8. Amin Al Olama, A, Benlloch, S, Antoniou, AC, Giles, GG, Severi, G, Neal, DE et al.. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. 2015;24 (7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. PubMed PMID:25837820 PubMed Central PMC4491026.
  9. Murtola, TJ, Wahlfors, T, Haring, A, Taari, K, Stenman, UH, Tammela, TL et al.. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. 2015;68 (6):1089-97. doi: 10.1016/j.eururo.2015.03.026. PubMed PMID:25819720 .
  10. Stegeman, S, Amankwah, E, Klein, K, O’Mara, TA, Kim, D, Lin, HY et al.. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. 2015;5 (4):368-79. doi: 10.1158/2159-8290.CD-14-1057. PubMed PMID:25691096 PubMed Central PMC4390388.
  11. Yen, AM, Auvinen, A, Schleutker, J, Wu, YY, Fann, JC, Tammela, T et al.. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants. 2015;75 (8):825-35. doi: 10.1002/pros.22964. PubMed PMID:25683204 .
  12. Laitinen, VH, Rantapero, T, Fischer, D, Vuorinen, EM, Tammela, TL, PRACTICAL Consortium et al.. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. 2015;136 (10):2316-27. doi: 10.1002/ijc.29276. PubMed PMID:25335771 PubMed Central PMC4355047.
  13. Panagiotou, OA, Travis, RC, Campa, D, Berndt, SI, Lindstrom, S, Kraft, P et al.. A genome-wide pleiotropy scan for prostate cancer risk. 2015;67 (4):649-57. doi: 10.1016/j.eururo.2014.09.020. PubMed PMID:25277271 PubMed Central PMC4359641.

Search PubMed

Tammela Group

Molecular Biology

 

2020
  1. Pöyhönen, A, Åkerla, J, Koskimäki, J, Tammela, TLJ, Auvinen, A. Seasonal changes in occurrence and severity of lower urinary tract symptoms-Tampere Aging Male Urologic Study (TAMUS). Low Urin Tract Symptoms. 2020; :. doi: 10.1111/luts.12353. PubMed PMID:33034153 .
  2. Kujala, MM, Tammela, TL, Pöyhönen, A, Forsell, T, Pasanen, S, Paananen, I et al.. Prevalence of autoimmune disorders among bladder pain syndrome patients’ relatives. 2020; :1-6. doi: 10.1080/21681805.2020.1821766. PubMed PMID:32964777 .
  3. Fizazi, K, Shore, N, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S et al.. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020;383 (11):1040-1049. doi: 10.1056/NEJMoa2001342. PubMed PMID:32905676 .
  4. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. 2020;15 (6):e0234269. doi: 10.1371/journal.pone.0234269. PubMed PMID:32598349 PubMed Central PMC7323967.
  5. Huynh-Le, MP, Fan, CC, Karunamuni, R, Walsh, EI, Turner, EL, Lane, JA et al.. A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. 2020;29 (9):1731-1738. doi: 10.1158/1055-9965.EPI-19-1527. PubMed PMID:32581112 PubMed Central PMC7483627.
  6. Kohvakka, A, Sattari, M, Shcherban, A, Annala, M, Urbanucci, A, Kesseli, J et al.. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. 2020;39 (30):5241-5251. doi: 10.1038/s41388-020-1365-6. PubMed PMID:32555329 .
  7. Karunamuni, RA, Huynh-Le, MP, Fan, CC, Eeles, RA, Easton, DF, Kote-Jarai, Z et al.. The effect of sample size on polygenic hazard models for prostate cancer. 2020;28 (10):1467-1475. doi: 10.1038/s41431-020-0664-2. PubMed PMID:32514134 .
  8. Talala, K, Heinävaara, S, Taari, K, Tammela, TLJ, Kujala, P, Stenman, UH et al.. Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer. 2020;9 (15):5643-5654. doi: 10.1002/cam4.3181. PubMed PMID:32500650 PubMed Central PMC7402814.
  9. Shore, ND, Saad, F, Cookson, MS, George, DJ, Saltzstein, DR, Tutrone, R et al.. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. 2020;382 (23):2187-2196. doi: 10.1056/NEJMoa2004325. PubMed PMID:32469183 .
  10. Kilpeläinen, TP, Talala, K, Taari, K, Raitanen, J, Kujala, P, Pylväläinen, J et al.. Patients’ education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer. Eur J Cancer. 2020;130 :204-210. doi: 10.1016/j.ejca.2020.02.045. PubMed PMID:32229417 .
  11. Rantapero, T, Wahlfors, T, Kähler, A, Hultman, C, Lindberg, J, Tammela, TL et al.. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. 2020;11 (3):. doi: 10.3390/genes11030314. PubMed PMID:32183364 PubMed Central PMC7140841.

Search PubMed

2019
  1. Pylväläinen, J, Talala, K, Murtola, T, Taari, K, Raitanen, J, Tammela, TL et al.. Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time. 2019;11 :923-932. doi: 10.2147/CLEP.S218697. PubMed PMID:31695505 PubMed Central PMC6805117.
  2. Booth, N, Rissanen, P, Tammela, TLJ, Kujala, P, Stenman, UH, Taari, K et al.. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data. 2019;14 (11):e0224479. doi: 10.1371/journal.pone.0224479. PubMed PMID:31689326 PubMed Central PMC6830755.
  3. Shore, N, Zurth, C, Fricke, R, Gieschen, H, Graudenz, K, Koskinen, M et al.. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. 2019;14 (5):527-539. doi: 10.1007/s11523-019-00674-0. PubMed PMID:31571095 PubMed Central PMC6797643.
  4. Hackman, G, Taari, K, Tammela, TL, Matikainen, M, Kouri, M, Joensuu, T et al.. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. Eur Urol. 2019;76 (5):586-595. doi: 10.1016/j.eururo.2019.07.001. PubMed PMID:31375279 .
  5. Santala, EEE, Kotsar, A, Veitonmäki, T, Tammela, TLJ, Murtola, TJ. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. 2019;53 (4):185-192. doi: 10.1080/21681805.2019.1634147. PubMed PMID:31250699 .
  6. Reza, M, Wirth, M, Tammela, T, Cicalese, V, Veiga, FG, Mulders, P et al.. Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. 2019; :. doi: 10.1016/j.euo.2019.05.002. PubMed PMID:31186177 .
  7. Carlsson, SV, Månsson, M, Moss, S, Kwiatkowski, M, Recker, F, Tammela, TLJ et al.. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?. Eur Urol. 2019;75 (6):1015-1022. doi: 10.1016/j.eururo.2019.03.010. PubMed PMID:30928162 PubMed Central PMC7526685.
  8. Talvitie, AM, Ojala, H, Tammela, T, Koivisto, AM, Pietilä, I. Factors related to self-rated health and life satisfaction one year after radical prostatectomy for localised prostate cancer: a cross-sectional survey. 2019;33 (3):688-697. doi: 10.1111/scs.12664. PubMed PMID:30866074 .
  9. Hugosson, J, Roobol, MJ, Månsson, M, Tammela, TLJ, Zappa, M, Nelen, V et al.. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76 (1):43-51. doi: 10.1016/j.eururo.2019.02.009. PubMed PMID:30824296 PubMed Central PMC7513694.
  10. Fizazi, K, Shore, N, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S et al.. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. 2019;380 (13):1235-1246. doi: 10.1056/NEJMoa1815671. PubMed PMID:30763142 .
  11. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort. 2019;22 (3):483-490. doi: 10.1038/s41391-019-0129-2. PubMed PMID:30696944 .
  12. Murtola, TJ, Sälli, SM, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. 2019;22 (3):453-460. doi: 10.1038/s41391-018-0123-0. PubMed PMID:30679762 .
  13. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2019;10 (1):382. doi: 10.1038/s41467-019-08293-z. PubMed PMID:30655571 PubMed Central PMC6336778.
  14. Lindberg, A, Talala, K, Kujala, P, Stenman, UH, Taari, K, Kilpeläinen, TP et al.. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. 2019;145 (3):632-638. doi: 10.1002/ijc.32129. PubMed PMID:30653262 .
  15. Vandekerkhove, G, Struss, WJ, Annala, M, Kallio, HML, Khalaf, D, Warner, EW et al.. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. 2019;75 (4):667-675. doi: 10.1016/j.eururo.2018.12.042. PubMed PMID:30638634 .
  16. Schumacher, FR, Olama, AAA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2019;51 (2):363. doi: 10.1038/s41588-018-0330-6. PubMed PMID:30622367 .
  17. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  18. Li-Sheng Chen, S, Ching-Yuan Fann, J, Sipeky, C, Yang, TK, Yueh-Hsia Chiu, S, Ming-Fang Yen, A et al.. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. 2019;201 (3):486-495. doi: 10.1016/j.juro.2018.10.015. PubMed PMID:30366021 .
  19. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  20. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  21. Nuotio, MS, Luukkaala, T, Tammela, T. Elevated post-void residual volume in a geriatric post-hip fracture assessment in women-associated factors and risk of mortality. 2019;31 (1):75-83. doi: 10.1007/s40520-018-0946-5. PubMed PMID:29633169 .
  22. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  23. Saarimäki, L, Hugosson, J, Tammela, TL, Carlsson, S, Talala, K, Auvinen, A et al.. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. 2019;5 (2):186-191. doi: 10.1016/j.euf.2017.07.007. PubMed PMID:28803925 PubMed Central PMC5809235.

Search PubMed

2018
  1. Siltari, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort. ;52 (5-6):321-327. doi: 10.1080/21681805.2018.1559882. PubMed PMID:30698056 .
  2. Åkerla, J, Pesonen, JS, Pöyhönen, A, Häkkinen, J, Koskimäki, J, Huhtala, H et al.. Impact of lower urinary tract symptoms on mortality: a 21-year follow-up among middle-aged and elderly Finnish men. 2019;22 (2):317-323. doi: 10.1038/s41391-018-0108-z. PubMed PMID:30410016 .
  3. Matejcic, M, Saunders, EJ, Dadaev, T, Brook, MN, Wang, K, Sheng, X et al.. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. 2018;9 (1):4616. doi: 10.1038/s41467-018-06863-1. PubMed PMID:30397198 PubMed Central PMC6218483.
  4. Pöyhönen, A, Åkerla, J, Häkkinen, JT, Koskimäki, J, Tammela, TLJ, Auvinen, A et al.. Severity and bother of lower urinary tract symptoms among men aged 30-80 years: Tampere Ageing Male Urological Study (TAMUS). 2018;52 (4):296-301. doi: 10.1080/21681805.2018.1505944. PubMed PMID:30382800 .
  5. Rantaniemi, L, Tammela, TLJ, Kujala, P, Murtola, TJ. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy. 2018;52 (4):269-276. doi: 10.1080/21681805.2018.1492967. PubMed PMID:30362865 .
  6. Pakarainen, T, Nevalainen, J, Talala, K, Taari, K, Raitanen, J, Kujala, P et al.. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). 2019;25 (2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. PubMed PMID:30322875 .
  7. Murtola, TJ, Kasurinen, TVJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. 2019;22 (1):66-76. doi: 10.1038/s41391-018-0087-0. PubMed PMID:30214034 .
  8. Sipeky, C, Gao, P, Zhang, Q, Wang, L, Ettala, O, Talala, KM et al.. Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer. 2018;24 (24):6265-6276. doi: 10.1158/1078-0432.CCR-18-0444. PubMed PMID:30181389 PubMed Central PMC6719560.
  9. Kaikkonen, E, Rantapero, T, Zhang, Q, Taimen, P, Laitinen, V, Kallajoki, M et al.. ANO7 is associated with aggressive prostate cancer. 2018;143 (10):2479-2487. doi: 10.1002/ijc.31746. PubMed PMID:30157291 PubMed Central PMC6589920.
  10. Gao, P, Xia, JH, Sipeky, C, Dong, XM, Zhang, Q, Yang, Y et al.. Biology and Clinical Implications of the 19q13 Aggressive Prostate Cancer Susceptibility Locus. 2018;174 (3):576-589.e18. doi: 10.1016/j.cell.2018.06.003. PubMed PMID:30033361 PubMed Central PMC6091222.
  11. Murtola, TJ, Syvälä, H, Tolonen, T, Helminen, M, Riikonen, J, Koskimäki, J et al.. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. 2018;74 (6):697-701. doi: 10.1016/j.eururo.2018.06.037. PubMed PMID:30031572 .
  12. Kallio, HML, Hieta, R, Latonen, L, Brofeldt, A, Annala, M, Kivinummi, K et al.. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. 2018;119 (3):347-356. doi: 10.1038/s41416-018-0172-0. PubMed PMID:29988112 PubMed Central PMC6070921.
  13. Kaapu, KJ, Rantaniemi, L, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men. 2018;8 (1):10308. doi: 10.1038/s41598-018-28541-4. PubMed PMID:29985440 PubMed Central PMC6037774.
  14. Dadaev, T, Saunders, EJ, Newcombe, PJ, Anokian, E, Leongamornlert, DA, Brook, MN et al.. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 2018;9 (1):2256. doi: 10.1038/s41467-018-04109-8. PubMed PMID:29892050 PubMed Central PMC5995836.
  15. Schumacher, FR, Al Olama, AA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ et al.. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2018;50 (7):928-936. doi: 10.1038/s41588-018-0142-8. PubMed PMID:29892016 PubMed Central PMC6568012.
  16. Tolonen, TT, Riikonen, J, Tammela, TLJ, Koivusalo, L, Haapasalo, H, Kujala, P et al.. Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. 2018;35 :80-84. doi: 10.1016/j.anndiagpath.2018.06.001. PubMed PMID:29886397 .
  17. Mäkelä, VJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. 2018;200 (4):743-748. doi: 10.1016/j.juro.2018.04.082. PubMed PMID:29730200 .
  18. Nuotio, MS, Luukkaala, T, Tammela, T. Elevated post-void residual volume in a geriatric post-hip fracture assessment in women-associated factors and risk of mortality. 2019;31 (1):75-83. doi: 10.1007/s40520-018-0946-5. PubMed PMID:29633169 .
  19. Ebbinge, M, Berglund, A, Varenhorst, E, Hedlund, PO, Sandblom, G, Scandinavian Prostate Cancer Group (SPCG)-5 Study Group et al.. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer. 2018;122 (4):583-591. doi: 10.1111/bju.14227. PubMed PMID:29611275 .
  20. Murtola, TJ, Vihervuori, VJ, Lahtela, J, Talala, K, Taari, K, Tammela, TL et al.. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2018;118 (9):1248-1254. doi: 10.1038/s41416-018-0055-4. PubMed PMID:29563633 PubMed Central PMC5943324.
  21. Latonen, L, Afyounian, E, Jylhä, A, Nättinen, J, Aapola, U, Annala, M et al.. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. 2018;9 (1):1176. doi: 10.1038/s41467-018-03573-6. PubMed PMID:29563510 PubMed Central PMC5862881.
  22. Booth, N, Rissanen, P, Tammela, TLJ, Taari, K, Talala, K, Auvinen, A et al.. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data. 2018;93 :108-118. doi: 10.1016/j.ejca.2018.01.111. PubMed PMID:29501976 .
  23. Pietilä, I, Jurva, R, Ojala, H, Tammela, T. Seeking certainty through narrative closure: men’s stories of prostate cancer treatments in a state of liminality. 2018;40 (4):639-653. doi: 10.1111/1467-9566.12671. PubMed PMID:29430679 .
  24. Smith, MR, Saad, F, Chowdhury, S, Oudard, S, Hadaschik, BA, Graff, JN et al.. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. 2018;378 (15):1408-1418. doi: 10.1056/NEJMoa1715546. PubMed PMID:29420164 .
  25. Ahlgren, GM, Flodgren, P, Tammela, TLJ, Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A et al.. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. 2018;73 (6):870-876. doi: 10.1016/j.eururo.2018.01.012. PubMed PMID:29395502 .
  26. Seibert, TM, Fan, CC, Wang, Y, Zuber, V, Karunamuni, R, Parsons, JK et al.. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 2018;360 :j5757. doi: 10.1136/bmj.j5757. PubMed PMID:29321194 PubMed Central PMC5759091.
  27. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  28. Neupane, S, Steyerberg, E, Raitanen, J, Talala, K, Pylväläinen, J, Taari, K et al.. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. 2018;25 (3):270-276. doi: 10.1111/iju.13508. PubMed PMID:29224236 .
  29. Högnäs, G, Kivinummi, K, Kallio, HML, Hieta, R, Ruusuvuori, P, Koskenalho, A et al.. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. 2018;42 (1):103-115. doi: 10.1097/PAS.0000000000000961. PubMed PMID:28984675 .
  30. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .
  31. Shore, ND, Tammela, TL, Massard, C, Bono, P, Aspegren, J, Mustonen, M et al.. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. 2018;4 (4):547-553. doi: 10.1016/j.euf.2017.01.015. PubMed PMID:28753851 .
  32. Lehto, US, Aromaa, A, Tammela, TL. Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. 2018;27 (1):. doi: 10.1111/ecc.12729. PubMed PMID:28634991 .

Search PubMed

2017
  1. Kukko, V, Kaipia, A, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. 2018;21 (3):373-378. doi: 10.1038/s41391-017-0031-8. PubMed PMID:29273728 .
  2. Kivinummi, K, Urbanucci, A, Leinonen, K, Tammela, TLJ, Annala, M, Isaacs, WB et al.. The expression of AURKA is androgen regulated in castration-resistant prostate cancer. 2017;7 (1):17978. doi: 10.1038/s41598-017-18210-3. PubMed PMID:29269934 PubMed Central PMC5740165.
  3. Neupane, S, Steyerberg, E, Raitanen, J, Talala, K, Pylväläinen, J, Taari, K et al.. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. 2018;25 (3):270-276. doi: 10.1111/iju.13508. PubMed PMID:29224236 .
  4. Assel, M, Sjöblom, L, Murtola, TJ, Talala, K, Kujala, P, Stenman, UH et al.. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. 2019;5 (4):561-567. doi: 10.1016/j.euf.2017.11.002. PubMed PMID:29137895 PubMed Central PMC5948115.
  5. Kinnunen, PTT, Murtola, TJ, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A et al.. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;17 (1):585. doi: 10.1186/s12885-017-3579-8. PubMed PMID:28851310 PubMed Central PMC5575900.
  6. Saarimäki, L, Hugosson, J, Tammela, TL, Carlsson, S, Talala, K, Auvinen, A et al.. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres. 2019;5 (2):186-191. doi: 10.1016/j.euf.2017.07.007. PubMed PMID:28803925 PubMed Central PMC5809235.
  7. Auvinen, A, Rannikko, A, Taari, K, Kujala, P, Mirtti, T, Kenttämies, A et al.. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. 2017;32 (6):521-527. doi: 10.1007/s10654-017-0292-5. PubMed PMID:28762124 .
  8. Murtola, TJ, Vettenranta, AM, Talala, K, Taari, K, Stenman, UH, Tammela, TLJ et al.. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. 2018;4 (6):851-857. doi: 10.1016/j.euf.2017.03.005. PubMed PMID:28753870 .
  9. Shore, ND, Tammela, TL, Massard, C, Bono, P, Aspegren, J, Mustonen, M et al.. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. 2018;4 (4):547-553. doi: 10.1016/j.euf.2017.01.015. PubMed PMID:28753851 .
  10. Fizazi, K, Massard, C, Bono, P, Kataja, V, James, N, Tammela, TL et al.. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. 2017;3 (6):606-614. doi: 10.1016/j.euf.2017.01.010. PubMed PMID:28753849 .
  11. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  12. Eskelinen, TJ, Kotsar, A, Tammela, TLJ, Murtola, TJ. Components of metabolic syndrome and prognosis of renal cell cancer. 2017;51 (6):435-441. doi: 10.1080/21681805.2017.1352616. PubMed PMID:28743221 .
  13. Tammela, TL, Häggman, M, Ladjevardi, S, Taari, K, Isotalo, T, Lennernäs, H et al.. An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. 2017;198 (6):1333-1339. doi: 10.1016/j.juro.2017.07.072. PubMed PMID:28736321 .
  14. Na, R, Helfand, BT, Chen, H, Conran, CA, Crawford, SE, Hayward, SW et al.. A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). 2017;77 (11):1213-1220. doi: 10.1002/pros.23380. PubMed PMID:28656603 PubMed Central PMC5565164.
  15. Väänänen, T, Kallio, J, Vuolteenaho, K, Ojala, A, Luukkaala, T, Hämäläinen, M et al.. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. 2017;51 (5):367-372. doi: 10.1080/21681805.2017.1327885. PubMed PMID:28644702 .
  16. Lehto, US, Aromaa, A, Tammela, TL. Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. 2018;27 (1):. doi: 10.1111/ecc.12729. PubMed PMID:28634991 .
  17. Urbanucci, A, Barfeld, SJ, Kytölä, V, Itkonen, HM, Coleman, IM, Vodák, D et al.. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. 2017;19 (10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. PubMed PMID:28591577 PubMed Central PMC5675034.
  18. Kallio, J, Hämäläinen, M, Luukkaala, T, Moilanen, E, Tammela, TL, Kellokumpu-Lehtinen, PL et al.. Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer. 2017;35 (9):544.e25-544.e31. doi: 10.1016/j.urolonc.2017.05.005. PubMed PMID:28572026 .
  19. Nygård, LH, Talala, K, Taari, K, Tammela, TLJ, Auvinen, A, Murtola, TJ et al.. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. 2017;77 (9):1029-1035. doi: 10.1002/pros.23359. PubMed PMID:28480542 .
  20. Murtola, TJ, Virkku, A, Talala, K, Stenman, UH, Taari, K, Tammela, TLJ et al.. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. 2017;198 (2):305-309. doi: 10.1016/j.juro.2017.02.069. PubMed PMID:28216328 .
  21. Kilpeläinen, TP, Pogodin-Hannolainen, D, Kemppainen, K, Talala, K, Raitanen, J, Taari, K et al.. Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;198 (1):50-57. doi: 10.1016/j.juro.2017.01.048. PubMed PMID:28104375 .
  22. Haring, A, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;51 (1):5-12. doi: 10.1080/21681805.2016.1271353. PubMed PMID:28084175 .
  23. Azzouzi, AR, Vincendeau, S, Barret, E, Cicco, A, Kleinclauss, F, van der Poel, HG et al.. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. 2017;18 (2):181-191. doi: 10.1016/S1470-2045(16)30661-1. PubMed PMID:28007457 .
  24. Nevalainen, J, Stenman, UH, Tammela, TL, Roobol, M, Carlsson, S, Talala, K et al.. What explains the differences between centres in the European screening trial? A simulation study. 2017;46 :14-19. doi: 10.1016/j.canep.2016.11.005. PubMed PMID:27889661 PubMed Central PMC5415347.
  25. Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS et al.. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. 2017;71 (2):151-154. doi: 10.1016/j.eururo.2016.07.032. PubMed PMID:27477525 PubMed Central PMC5570461.

Search PubMed

2016
  1. Murtola, TJ, Peltomaa, AI, Talala, K, Määttänen, L, Taari, K, Tammela, TLJ et al.. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2017;3 (2-3):212-220. doi: 10.1016/j.euf.2016.05.004. PubMed PMID:28753762 .
  2. Azzouzi, AR, Vincendeau, S, Barret, E, Cicco, A, Kleinclauss, F, van der Poel, HG et al.. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. 2017;18 (2):181-191. doi: 10.1016/S1470-2045(16)30661-1. PubMed PMID:28007457 .
  3. Nevalainen, J, Stenman, UH, Tammela, TL, Roobol, M, Carlsson, S, Talala, K et al.. What explains the differences between centres in the European screening trial? A simulation study. 2017;46 :14-19. doi: 10.1016/j.canep.2016.11.005. PubMed PMID:27889661 PubMed Central PMC5415347.
  4. Syvälä, H, Pennanen, P, Bläuer, M, Tammela, TL, Murtola, TJ. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. 2016;481 (1-2):46-50. doi: 10.1016/j.bbrc.2016.11.021. PubMed PMID:27833018 .
  5. Kinnunen, PT, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;50 (6):413-419. doi: 10.1080/21681805.2016.1228085. PubMed PMID:27628763 .
  6. Luedeke, M, Rinckleb, AE, FitzGerald, LM, Geybels, MS, Schleutker, J, Eeles, RA et al.. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. 2016;25 (24):5490-5499. doi: 10.1093/hmg/ddw349. PubMed PMID:27798103 PubMed Central PMC5418832.
  7. Kilpeläinen, TP, Talala, K, Raitanen, J, Taari, K, Kujala, P, Tammela, TLJ et al.. Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;184 (10):720-731. doi: 10.1093/aje/kww084. PubMed PMID:27777219 .
  8. Kaapu, KJ, Murtola, TJ, Talala, K, Taari, K, Tammela, TL, Auvinen, A et al.. Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;115 (11):1289-1295. doi: 10.1038/bjc.2016.328. PubMed PMID:27755533 PubMed Central PMC5129833.
  9. Kilpeläinen, TP, Mäkinen, T, Karhunen, PJ, Aro, J, Lahtela, J, Taari, K et al.. Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer. 2016;45 :1-5. doi: 10.1016/j.canep.2016.08.022. PubMed PMID:27636505 .
  10. Beer, TM, Armstrong, AJ, Rathkopf, D, Loriot, Y, Sternberg, CN, Higano, CS et al.. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. 2017;71 (2):151-154. doi: 10.1016/j.eururo.2016.07.032. PubMed PMID:27477525 PubMed Central PMC5570461.
  11. Kar, SP, Beesley, J, Amin Al Olama, A, Michailidou, K, Tyrer, J, Kote-Jarai, Z et al.. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 2016;6 (9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. PubMed PMID:27432226 PubMed Central PMC5010513.
  12. Pöyhönen, A, Auvinen, A, Häkkinen, JT, Koskimäki, J, Tammela, TL. Population-level and Individual-level Bother of Lower Urinary Tract Symptoms Among 30- to 80-year-old Men. 2016;95 :164-70. doi: 10.1016/j.urology.2016.06.023. PubMed PMID:27349526 .
  13. Pennanen, P, Syvälä, H, Bläuer, M, Savinainen, K, Ylikomi, T, Tammela, TLJ et al.. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines. 2016;788 :160-167. doi: 10.1016/j.ejphar.2016.06.036. PubMed PMID:27341997 .
  14. Teerlink, CC, Leongamornlert, D, Dadaev, T, Thomas, A, Farnham, J, Stephenson, RA et al.. Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. 2016;135 (8):923-38. doi: 10.1007/s00439-016-1690-6. PubMed PMID:27262462 PubMed Central PMC5020907.
  15. Pakarainen, T, Raitanen, J, Talala, K, Taari, K, Kujala, P, Tammela, TL et al.. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study. 2016;70 (3):499-505. doi: 10.1016/j.eururo.2016.05.009. PubMed PMID:27210461 .
  16. Nurminen, R, Rantapero, T, Wong, SC, Fischer, D, Lehtonen, R, Tammela, TL et al.. Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. 2016;55 (8):661-73. doi: 10.1002/gcc.22368. PubMed PMID:27113481 .
  17. Veitonmäki, T, Murtola, TJ, Talala, K, Taari, K, Tammela, T, Auvinen, A et al.. Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial. 2016;11 (4):e0153413. doi: 10.1371/journal.pone.0153413. PubMed PMID:27100876 PubMed Central PMC4839624.
  18. Marttila, T, Järvinen, R, Liukkonen, T, Rintala, E, Boström, P, Seppänen, M et al.. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. 2016;70 (2):341-7. doi: 10.1016/j.eururo.2016.03.034. PubMed PMID:27085624 .
  19. Latonen, L, Leinonen, KA, Grönlund, T, Vessella, RL, Tammela, TL, Saramäki, OR et al.. Amplification of the 9p13.3 chromosomal region in prostate cancer. 2016;55 (8):617-25. doi: 10.1002/gcc.22364. PubMed PMID:27074291 .
  20. Gusev, A, Shi, H, Kichaev, G, Pomerantz, M, Li, F, Long, HW et al.. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. 2016;7 :10979. doi: 10.1038/ncomms10979. PubMed PMID:27052111 PubMed Central PMC4829663.
  21. Salminen, JK, Tammela, TL, Auvinen, A, Murtola, TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. 2016;27 (5):637-45. doi: 10.1007/s10552-016-0737-2. PubMed PMID:27038166 .
  22. Sjöblom, L, Saramäki, O, Annala, M, Leinonen, K, Nättinen, J, Tolonen, T et al.. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. 2016;11 (3):e0150241. doi: 10.1371/journal.pone.0150241. PubMed PMID:26939004 PubMed Central PMC4777373.
  23. Sarre, S, Määttänen, L, Tammela, TL, Auvinen, A, Murtola, TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. 2016;50 (4):267-73. doi: 10.3109/21681805.2016.1145734. PubMed PMID:26927237 .
  24. Pesonen, JS, Cartwright, R, Mangera, A, Santti, H, Griebling, TL, Pryalukhin, AE et al.. Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis. 2016;70 (2):372-81. doi: 10.1016/j.eururo.2016.02.014. PubMed PMID:26905787 .
  25. Murtola, TJ, Karppa, EK, Taari, K, Talala, K, Tammela, TL, Auvinen, A et al.. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. 2016;138 (12):2820-8. doi: 10.1002/ijc.30017. PubMed PMID:26804670 .
  26. Keskiväli, T, Kujala, P, Visakorpi, T, Tammela, TL, Murtola, TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. 2016;76 (5):469-78. doi: 10.1002/pros.23138. PubMed PMID:26689439 .
  27. Laitinen, VH, Akinrinade, O, Rantapero, T, Tammela, TL, Wahlfors, T, Schleutker, J et al.. Germline copy number variation analysis in Finnish families with hereditary prostate cancer. 2016;76 (3):316-24. doi: 10.1002/pros.23123. PubMed PMID:26552734 .
  28. Schulman, C, Cornel, E, Matveev, V, Tammela, TL, Schraml, J, Bensadoun, H et al.. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). 2016;69 (4):720-727. doi: 10.1016/j.eururo.2015.10.007. PubMed PMID:26520703 .
  29. Massard, C, Penttinen, HM, Vjaters, E, Bono, P, Lietuvietis, V, Tammela, TL et al.. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. 2016;69 (5):834-40. doi: 10.1016/j.eururo.2015.09.046. PubMed PMID:26463318 .
  30. Auvinen, A, Moss, SM, Tammela, TL, Taari, K, Roobol, MJ, Schröder, FH et al.. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. 2016;22 (1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. PubMed PMID:26289069 PubMed Central PMC4951205.

Search PubMed

2015
  1. Keskiväli, T, Kujala, P, Visakorpi, T, Tammela, TL, Murtola, TJ. Statin use and risk of disease recurrence and death after radical prostatectomy. 2016;76 (5):469-78. doi: 10.1002/pros.23138. PubMed PMID:26689439 .
  2. Laitinen, VH, Akinrinade, O, Rantapero, T, Tammela, TL, Wahlfors, T, Schleutker, J et al.. Germline copy number variation analysis in Finnish families with hereditary prostate cancer. 2016;76 (3):316-24. doi: 10.1002/pros.23123. PubMed PMID:26552734 .
  3. Schulman, C, Cornel, E, Matveev, V, Tammela, TL, Schraml, J, Bensadoun, H et al.. Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND). 2016;69 (4):720-727. doi: 10.1016/j.eururo.2015.10.007. PubMed PMID:26520703 .
  4. Massard, C, Penttinen, HM, Vjaters, E, Bono, P, Lietuvietis, V, Tammela, TL et al.. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study. 2016;69 (5):834-40. doi: 10.1016/j.eururo.2015.09.046. PubMed PMID:26463318 .
  5. Davies, NM, Gaunt, TR, Lewis, SJ, Holly, J, Donovan, JL, Hamdy, FC et al.. The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. 2015;26 (11):1603-16. doi: 10.1007/s10552-015-0654-9. PubMed PMID:26387087 PubMed Central PMC4596899.
  6. Szulkin, R, Karlsson, R, Whitington, T, Aly, M, Gronberg, H, Eeles, RA et al.. Genome-wide association study of prostate cancer-specific survival. 2015;24 (11):1796-800. doi: 10.1158/1055-9965.EPI-15-0543. PubMed PMID:26307654 PubMed Central PMC5674990.
  7. Pashayan, N, Pharoah, PD, Schleutker, J, Talala, K, Tammela, TLj, Määttänen, L et al.. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. 2015;113 (7):1086-93. doi: 10.1038/bjc.2015.289. PubMed PMID:26291059 PubMed Central PMC4651137.
  8. Auvinen, A, Moss, SM, Tammela, TL, Taari, K, Roobol, MJ, Schröder, FH et al.. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening. 2016;22 (1):243-9. doi: 10.1158/1078-0432.CCR-15-0941. PubMed PMID:26289069 PubMed Central PMC4951205.
  9. Ylipää, A, Kivinummi, K, Kohvakka, A, Annala, M, Latonen, L, Scaravilli, M et al.. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. 2015;75 (19):4026-31. doi: 10.1158/0008-5472.CAN-15-0217. PubMed PMID:26282172 .
  10. Szulkin, R, Whitington, T, Eklund, M, Aly, M, Eeles, RA, Easton, D et al.. Prediction of individual genetic risk to prostate cancer using a polygenic score. 2015;75 (13):1467-74. doi: 10.1002/pros.23037. PubMed PMID:26177737 .
  11. Kaukoniemi, KM, Rauhala, HE, Scaravilli, M, Latonen, L, Annala, M, Vessella, RL et al.. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. 2015;4 (9):1417-25. doi: 10.1002/cam4.486. PubMed PMID:26129688 PubMed Central PMC4567026.
  12. Veitonmäki, T, Murtola, TJ, Määttänen, L, Taari, K, Stenman, UH, Tammela, TL et al.. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. 2015;75 (13):1394-402. doi: 10.1002/pros.23020. PubMed PMID:26073992 .
  13. Amin Al Olama, A, Dadaev, T, Hazelett, DJ, Li, Q, Leongamornlert, D, Saunders, EJ et al.. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. 2015;24 (19):5589-602. doi: 10.1093/hmg/ddv203. PubMed PMID:26025378 PubMed Central PMC4572072.
  14. Fischer, D, Wahlfors, T, Mattila, H, Oja, H, Tammela, TL, Schleutker, J et al.. MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families. 2015;10 (5):e0127427. doi: 10.1371/journal.pone.0127427. PubMed PMID:26020509 PubMed Central PMC4447459.
  15. Thomsen, FB, Brasso, K, Christensen, IJ, Johansson, JE, Angelsen, A, Tammela, TL et al.. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. 2015;51 (10):1283-92. doi: 10.1016/j.ejca.2015.03.021. PubMed PMID:25892647 .
  16. Amin Al Olama, A, Benlloch, S, Antoniou, AC, Giles, GG, Severi, G, Neal, DE et al.. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. 2015;24 (7):1121-9. doi: 10.1158/1055-9965.EPI-14-0317. PubMed PMID:25837820 PubMed Central PMC4491026.
  17. Murtola, TJ, Wahlfors, T, Haring, A, Taari, K, Stenman, UH, Tammela, TL et al.. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin. 2015;68 (6):1089-97. doi: 10.1016/j.eururo.2015.03.026. PubMed PMID:25819720 .
  18. Buzzoni, C, Auvinen, A, Roobol, MJ, Carlsson, S, Moss, SM, Puliti, D et al.. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. 2015;68 (5):885-90. doi: 10.1016/j.eururo.2015.02.042. PubMed PMID:25791513 PubMed Central PMC4982869.
  19. Annala, M, Kivinummi, K, Tuominen, J, Karakurt, S, Granberg, K, Latonen, L et al.. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. 2015;6 (8):6235-50. doi: 10.18632/oncotarget.3359. PubMed PMID:25749039 PubMed Central PMC4467434.
  20. Scaravilli, M, Porkka, KP, Brofeldt, A, Annala, M, Tammela, TL, Jenster, GW et al.. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. 2015;75 (8):798-805. doi: 10.1002/pros.22961. PubMed PMID:25731699 .
  21. Osman, NI, Chapple, CR, Tammela, TL, Eisenhardt, A, Oelke, M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. 2015;33 (5):697-706. doi: 10.1007/s00345-015-1519-2. PubMed PMID:25712312 .
  22. Stegeman, S, Amankwah, E, Klein, K, O’Mara, TA, Kim, D, Lin, HY et al.. A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. 2015;5 (4):368-79. doi: 10.1158/2159-8290.CD-14-1057. PubMed PMID:25691096 PubMed Central PMC4390388.
  23. Yen, AM, Auvinen, A, Schleutker, J, Wu, YY, Fann, JC, Tammela, T et al.. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants. 2015;75 (8):825-35. doi: 10.1002/pros.22964. PubMed PMID:25683204 .
  24. Kaapu, KJ, Ahti, J, Tammela, TL, Auvinen, A, Murtola, TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. 2015;137 (5):1187-95. doi: 10.1002/ijc.29470. PubMed PMID:25656312 .
  25. Uurto, I, Hämäläinen, M, Suominen, V, Laurila, M, Kotsar, A, Isotalo, T et al.. Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries. 2015;26 (1):124-30. doi: 10.1016/j.jvir.2014.10.005. PubMed PMID:25454655 .
  26. Kilpeläinen, TP, Tammela, TL, Malila, N, Hakama, M, Santti, H, Määttänen, L et al.. The Finnish prostate cancer screening trial: analyses on the screening failures. 2015;136 (10):2437-43. doi: 10.1002/ijc.29300. PubMed PMID:25359457 .
  27. Laitinen, VH, Rantapero, T, Fischer, D, Vuorinen, EM, Tammela, TL, PRACTICAL Consortium et al.. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. 2015;136 (10):2316-27. doi: 10.1002/ijc.29276. PubMed PMID:25335771 PubMed Central PMC4355047.
  28. Saarimäki, L, Tammela, TL, Määttänen, L, Taari, K, Kujala, PM, Raitanen, J et al.. Family history in the Finnish Prostate Cancer Screening Trial. 2015;136 (9):2172-7. doi: 10.1002/ijc.29243. PubMed PMID:25274038 .
  29. Wirth, M, Tammela, T, Cicalese, V, Gomez Veiga, F, Delaere, K, Miller, K et al.. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). 2015;67 (3):482-91. doi: 10.1016/j.eururo.2014.02.014. PubMed PMID:24630685 .

Search PubMed

Tolonen Group

Histopathology

2020
  1. Kontunen, A, Tuominen, J, Karjalainen, M, Anttalainen, O, Tolonen, T, Kumpulainen, P et al.. Differential mobility spectrometry imaging for pathological applications. Exp Mol Pathol. 2020;117 :104526. doi: 10.1016/j.yexmp.2020.104526. PubMed PMID:32888958 .
  2. Savolainen, K, Scaravilli, M, Ilvesmäki, A, Staff, S, Tolonen, T, Mäenpää, JU et al.. Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts. 2020;13 (1):311. doi: 10.1186/s13104-020-05155-6. PubMed PMID:32611374 PubMed Central PMC7329467.
  3. Hietanen, KE, Järvinen, TAH, Huhtala, H, Tolonen, TT, Kaartinen, IS. Histopathology and immunohistochemical analysis of 5-fluorouracil and triamcinolone treated keloids in double-blinded randomized controlled trial. 2020;28 (3):385-399. doi: 10.1111/wrr.12803. PubMed PMID:32112591 .
  4. Valkonen, M, Isola, J, Ylinen, O, Muhonen, V, Saxlin, A, Tolonen, T et al.. Cytokeratin-Supervised Deep Learning for Automatic Recognition of Epithelial Cells in Breast Cancers Stained for ER, PR, and Ki-67. 2020;39 (2):534-542. doi: 10.1109/TMI.2019.2933656. PubMed PMID:31398111 .

Search PubMed

2019
  1. Valkonen, M, Isola, J, Ylinen, O, Muhonen, V, Saxlin, A, Tolonen, T et al.. Cytokeratin-Supervised Deep Learning for Automatic Recognition of Epithelial Cells in Breast Cancers Stained for ER, PR, and Ki-67. 2020;39 (2):534-542. doi: 10.1109/TMI.2019.2933656. PubMed PMID:31398111 .
  2. Sutinen, M, Kontunen, A, Karjalainen, M, Kiiski, J, Hannus, J, Tolonen, T et al.. Identification of breast tumors from diathermy smoke by differential ion mobility spectrometry. 2019;45 (2):141-146. doi: 10.1016/j.ejso.2018.09.005. PubMed PMID:30366874 .

Search PubMed

2018
  1. Sutinen, M, Kontunen, A, Karjalainen, M, Kiiski, J, Hannus, J, Tolonen, T et al.. Identification of breast tumors from diathermy smoke by differential ion mobility spectrometry. 2019;45 (2):141-146. doi: 10.1016/j.ejso.2018.09.005. PubMed PMID:30366874 .
  2. Murtola, TJ, Syvälä, H, Tolonen, T, Helminen, M, Riikonen, J, Koskimäki, J et al.. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. 2018;74 (6):697-701. doi: 10.1016/j.eururo.2018.06.037. PubMed PMID:30031572 .
  3. Helin, H, Tolonen, T, Ylinen, O, Tolonen, P, Näpänkangas, J, Isola, J et al.. Optimized JPEG 2000 Compression for Efficient Storage of Histopathological Whole-Slide Images. 2018;9 :20. doi: 10.4103/jpi.jpi_69_17. PubMed PMID:29910969 PubMed Central PMC5989536.
  4. Tolonen, TT, Riikonen, J, Tammela, TLJ, Koivusalo, L, Haapasalo, H, Kujala, P et al.. Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease. 2018;35 :80-84. doi: 10.1016/j.anndiagpath.2018.06.001. PubMed PMID:29886397 .
  5. Sainio, M, Visakorpi, T, Tolonen, T, Ilvesaro, J, Bova, GS. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer. 2018;214 (6):848-856. doi: 10.1016/j.prp.2018.04.015. PubMed PMID:29728311 .
  6. Koivusalo, L, Kaipia, A, Kujala, P, Isola, J, Tolonen, TT. Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies. 2018;33 (4):399-405. doi: 10.14670/HH-11-940. PubMed PMID:29058306 .
  7. Högnäs, G, Kivinummi, K, Kallio, HML, Hieta, R, Ruusuvuori, P, Koskenalho, A et al.. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. 2018;42 (1):103-115. doi: 10.1097/PAS.0000000000000961. PubMed PMID:28984675 .

Search PubMed

2017
  1. Koivusalo, L, Kaipia, A, Kujala, P, Isola, J, Tolonen, TT. Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies. 2018;33 (4):399-405. doi: 10.14670/HH-11-940. PubMed PMID:29058306 .
  2. Urbanucci, A, Barfeld, SJ, Kytölä, V, Itkonen, HM, Coleman, IM, Vodák, D et al.. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. 2017;19 (10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. PubMed PMID:28591577 PubMed Central PMC5675034.

Search PubMed

2016
  1. Bova, GS, Kallio, HM, Annala, M, Kivinummi, K, Högnäs, G, Häyrynen, S et al.. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. 2016;2 (3):a000752. doi: 10.1101/mcs.a000752. PubMed PMID:27148588 PubMed Central PMC4853517.
  2. Sjöblom, L, Saramäki, O, Annala, M, Leinonen, K, Nättinen, J, Tolonen, T et al.. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. 2016;11 (3):e0150241. doi: 10.1371/journal.pone.0150241. PubMed PMID:26939004 PubMed Central PMC4777373.

Search PubMed